<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>451</serviceExecutionTime><Drug id="50259"><DrugName>selexipag</DrugName><DrugNamesKey><Name id="43048192">Uptravi</Name><Name id="42920874">selexipag</Name></DrugNamesKey><DrugSynonyms><Name><Value>MRE-269</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>MRE-304</Value><Types><Type>Research Code</Type><Type>Prodrug</Type></Types></Name><Name><Value>prostacyclin receptor agonists (vascular disease), Nippon Shinyaku</Value></Name><Name><Value>NS-304</Value><Types><Type>Research Code</Type><Type>Prodrug</Type></Types></Name><Name><Value>ACT-293987</Value><Types><Type>Research Code</Type><Type>Prodrug</Type></Types></Name><Name><Value>PGI2 receptor agonist (pulmonary hypertension), Acetlion/Nippon Shinyaku</Value></Name><Name><Value>selexipag</Value><Types><Type>USAN</Type><Type>INN</Type><Type>Prodrug</Type></Types></Name><Name><Value>ACT-333679</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>ACT-33679</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Uptravi</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>475086-01-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18552">Nippon Shinyaku Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="17332">Johnson &amp; Johnson</Company><Company id="19986">Handok Inc</Company><Company id="18552">Nippon Shinyaku Co Ltd</Company><Company id="23780">Actelion Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="50259" type="Drug"><TargetEntity id="330079" type="siDrug">Selexipag</TargetEntity></SourceEntity><SourceEntity id="17332" type="Company"><TargetEntity id="4295904341" type="organizationId">Johnson &amp; Johnson</TargetEntity></SourceEntity><SourceEntity id="18552" type="Company"><TargetEntity id="4295877838" type="organizationId">Nippon Shinyaku Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19986" type="Company"><TargetEntity id="4295881029" type="organizationId">Handok Inc</TargetEntity></SourceEntity><SourceEntity id="23780" type="Company"><TargetEntity id="4295890901" type="organizationId">Actelion Ltd</TargetEntity></SourceEntity><SourceEntity id="3137" type="ciIndication"><TargetEntity id="M48.0" type="ICD10"></TargetEntity><TargetEntity id="10041540" type="MEDDRA"></TargetEntity><TargetEntity id="D013130" type="MeSH"></TargetEntity><TargetEntity id="-286867296" type="omicsDisease"></TargetEntity><TargetEntity id="1177" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3510" type="ciIndication"><TargetEntity id="I27.0" type="ICD10"></TargetEntity><TargetEntity id="10064911" type="MEDDRA"></TargetEntity><TargetEntity id="182090" type="ORPHANET"></TargetEntity><TargetEntity id="244" type="siCondition"></TargetEntity><TargetEntity id="2543" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3513" type="ciIndication"><TargetEntity id="70591" type="ORPHANET"></TargetEntity><TargetEntity id="2074" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="478" type="ciIndication"><TargetEntity id="I73.0" type="ICD10"></TargetEntity><TargetEntity id="10037912" type="MEDDRA"></TargetEntity><TargetEntity id="D011928" type="MeSH"></TargetEntity><TargetEntity id="-140562337" type="omicsDisease"></TargetEntity><TargetEntity id="263" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="540" type="ciIndication"><TargetEntity id="10003210" type="MEDDRA"></TargetEntity><TargetEntity id="D001161" type="MeSH"></TargetEntity><TargetEntity id="-1473236367" type="omicsDisease"></TargetEntity><TargetEntity id="207" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3466" type="Action"><TargetEntity id="288" type="Mechanism">Prostanoid IP Agonists</TargetEntity></SourceEntity><SourceEntity id="327" type="Action"><TargetEntity id="297" type="Mechanism">Prostacyclin Analogs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Pulmonary artery hypertension - US - Jan-2016</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3137">Spinal stenosis</Indication><Indication id="3510">Pulmonary artery hypertension</Indication><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><Indication id="540">Arteriosclerosis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="478">Raynauds disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="3466">IP prostanoid receptor agonist</Action><Action id="327">PGI2 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action><Action id="388">Vasodilator</Action></ActionsSecondary><Technologies><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-21T08:39:43.000Z</LastModificationDate><ChangeDateLast>2019-06-24T00:00:00.000Z</ChangeDateLast><AddedDate>2004-06-02T14:40:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18552" linkType="Company"&gt;Nippon Shinyaku&lt;/ulink&gt; and licensee &lt;ulink linkID="17332" linkType="Company"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="23780" linkType="Company"&gt;Actelion&lt;/ulink&gt;, have developed and launched the non-prostanoid prostacyclin (PGI2) receptor agonist selexipag (Uptravi; NS-304; ACT-293987; MRE-304), the prodrug of MRE-269 [&lt;ulink linkID="634927" linkType="Reference"&gt;634927&lt;/ulink&gt;], [&lt;ulink linkID="898522" linkType="Reference"&gt;898522&lt;/ulink&gt;], [&lt;ulink linkID="1206198" linkType="Reference"&gt;1206198&lt;/ulink&gt;], [&lt;ulink linkID="1646151" linkType="Reference"&gt;1646151&lt;/ulink&gt;]. The product is indicated in the US for the treatment of pulmonary arterial hypertension (PAH; WHO group 1) to delay disease progression and reduce the risk of hospitalization for PAH [&lt;ulink linkID="1726829" linkType="Reference"&gt;1726829&lt;/ulink&gt;]. In Europe, the drug is indicated  for the long-term treatment of PAH in adults with WHO functional class II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist and/or PDE-5 inhibitor, or as monotherapy in patients who are not candidates for these therapies [&lt;ulink linkID="1763240" linkType="Reference"&gt;1763240&lt;/ulink&gt;]. In Japan, selexipag is indicated for the treatment of  PAH [&lt;ulink linkID="1802950" linkType="Reference"&gt;1802950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January  2016, selexipag was launched in the US for the treatment of PAH [&lt;ulink linkID="1726726" linkType="Reference"&gt;1726726&lt;/ulink&gt;], [&lt;ulink linkID="1904147" linkType="Reference"&gt;1904147&lt;/ulink&gt;]. In May 2016, the product was launched in France following approval in Europe for  PAH [&lt;ulink linkID="1763217" linkType="Reference"&gt;1763217&lt;/ulink&gt;], [&lt;ulink linkID="1907982" linkType="Reference"&gt;1907982&lt;/ulink&gt;]; in June 2016, the drug was launched  in Germany [&lt;ulink linkID="1773336" linkType="Reference"&gt;1773336&lt;/ulink&gt;], [&lt;ulink linkID="1904147" linkType="Reference"&gt;1904147&lt;/ulink&gt;]. In November 2016, the drug was launched in Japan for PAH [&lt;ulink linkID="1877316" linkType="Reference"&gt;1877316&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug is also being developed for other indications, including chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4), arteriosclerosis obliterans and spinal canal stenosis  [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;],   [&lt;ulink linkID="2018730" linkType="Reference"&gt;2018730&lt;/ulink&gt;]. In June 2016, a phase III study began   in Japanese patients with CTPH  [&lt;ulink linkID="1774606" linkType="Reference"&gt;1774606&lt;/ulink&gt;], [&lt;ulink linkID="1775039" linkType="Reference"&gt;1775039&lt;/ulink&gt;]; in July 2018, phase III development in this setting was ongoing [&lt;ulink linkID="2078735" linkType="Reference"&gt;2078735&lt;/ulink&gt;]. In July 2018, a late phase II trial for arteriosclerosis obliterans was ongoing [&lt;ulink linkID="2075572" linkType="Reference"&gt;2075572&lt;/ulink&gt;],  [&lt;ulink linkID="2078735" linkType="Reference"&gt;2078735&lt;/ulink&gt;]. In February 2018, a phase II trial for lumbar spinal canal stenosis was initiated [&lt;ulink linkID="2018730" linkType="Reference"&gt;2018730&lt;/ulink&gt;]. In May 2019, a  phase II/III trial in sarcoidosis-associated pulmonary hypertension (SAPH) was to begin in August 2019   [&lt;ulink linkID="2150908" linkType="Reference"&gt;2150908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Selexipag was previously being developed for Raynaud's disease. In October 2014, a  phase II trial began in subjects with Raynaud's phenomenon secondary to systemic sclerosis [&lt;ulink linkID="1601898" linkType="Reference"&gt;1601898&lt;/ulink&gt;]. By July 2015, efficacy data had been obtained, which did not support further pursuit of that indication [&lt;ulink linkID="1679169" linkType="Reference"&gt;1679169&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also developing an iv formlation of the drug for PAH patients already treated with oral selexipag. By June 2017, phase III trials were initiated [&lt;ulink linkID="2002159" linkType="Reference"&gt;2002159&lt;/ulink&gt;]. In January 2018, the iv formulation was listed as being in phase III  development in the US and  Europe [&lt;ulink linkID="2002061" linkType="Reference"&gt;2002061&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The constraining product patent in the US, &lt;ulink linkID="PA2982938" linkType="Patent"&gt;US-07205302&lt;/ulink&gt;, expires in April 2023. SPCs have been granted on &lt;ulink linkID="PA3316304" linkType="Patent"&gt;EP-01400518&lt;/ulink&gt; in most European countries and expire in April 2027.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2014,   an NDA was filed  for  PAH [&lt;ulink linkID="1622653" linkType="Reference"&gt;1622653&lt;/ulink&gt;]. In March 2015, the FDA accepted the NDA for review [&lt;ulink linkID="1638548" linkType="Reference"&gt;1638548&lt;/ulink&gt;].  In December 2015, selexipag was approved in the US for PAH [&lt;ulink linkID="1723099" linkType="Reference"&gt;1723099&lt;/ulink&gt;]. In January 2016, the product was launched [&lt;ulink linkID="1726726" linkType="Reference"&gt;1726726&lt;/ulink&gt;], [&lt;ulink linkID="1904147" linkType="Reference"&gt;1904147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, selexipag was designated an Orphan Drug by the FDA [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;]. In October 2018, the FDA granted selexipag Orphan designation for treatment of CTEPH [&lt;ulink linkID="2112392" linkType="Reference"&gt;2112392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By March 2015, a regulatory submission had been filed in Switzerland for PAH [&lt;ulink linkID="1638548" linkType="Reference"&gt;1638548&lt;/ulink&gt;]; in December 2015, regulatory review was ongoing [&lt;ulink linkID="1723099" linkType="Reference"&gt;1723099&lt;/ulink&gt;]; in March 2016, that was still the case [&lt;ulink linkID="1745410" linkType="Reference"&gt;1745410&lt;/ulink&gt;]. In August 2016, the drug was approved for PAH in Switzerland; at that time, launch was expected "as soon as possible" [&lt;ulink linkID="1788525" linkType="Reference"&gt;1788525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, Actelion submitted a centralized MAA to the EMA for the drug in the treatment of PAH [&lt;ulink linkID="1617245" linkType="Reference"&gt;1617245&lt;/ulink&gt;]; in January 2016, the EMA's CHMP recommended approval in the EU for the treatment of PAH [&lt;ulink linkID="1731051" linkType="Reference"&gt;1731051&lt;/ulink&gt;], [&lt;ulink linkID="1731047" linkType="Reference"&gt;1731047&lt;/ulink&gt;]; in April 2016, the EMA's CHMP readopted the positive opinion as part of a clarification requested by the EC [&lt;ulink linkID="1748376" linkType="Reference"&gt;1748376&lt;/ulink&gt;]. In May 2016, the drug was approved in Europe [&lt;ulink linkID="1763217" linkType="Reference"&gt;1763217&lt;/ulink&gt;]; at that time,  the drug was launched in France    [&lt;ulink linkID="1907982" linkType="Reference"&gt;1907982&lt;/ulink&gt;]; in June 2016, the drug was launched  in Germany [&lt;ulink linkID="1773336" linkType="Reference"&gt;1773336&lt;/ulink&gt;], [&lt;ulink linkID="1904147" linkType="Reference"&gt;1904147&lt;/ulink&gt;]. By October 2016, the drug was launched in the Netherlands [&lt;ulink linkID="1865402" linkType="Reference"&gt;1865402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, selexipag was designated an Orphan Drug for PAH by the EMA [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;] following its recommendation the previous month [&lt;ulink linkID="613808" linkType="Reference"&gt;613808&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In January 2016, Nippon Shinyaku submitted a Japanese filing for PAH [&lt;ulink linkID="1726726" linkType="Reference"&gt;1726726&lt;/ulink&gt;]. In September 2016, the first committee on New drugs of the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) of the Ministry of Health, Labour and Welfare (MHLW) recommended approval for PAH  [&lt;ulink linkID="1798140" linkType="Reference"&gt;1798140&lt;/ulink&gt;]. Later that month, the product was approved in Japan for the treatment of PAH [&lt;ulink linkID="1802950" linkType="Reference"&gt;1802950&lt;/ulink&gt;], [&lt;ulink linkID="1797650" linkType="Reference"&gt;1797650&lt;/ulink&gt;]. In November 2016, the drug was launched in Japan for PAH [&lt;ulink linkID="1877316" linkType="Reference"&gt;1877316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, filings for CTPH and arteriosclerosis obliterans were expected in fiscal year 2016 or later  [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, the Pharmaceutical Affairs and Food Sanitation Council's First Committee on Drugs was to discuss whether to  grant selexipag Orphan drug status at a meeting scheduled for September 04, 2014 [&lt;ulink linkID="1598358" linkType="Reference"&gt;1598358&lt;/ulink&gt;]. In September 2014, Orphan designation for PAH was granted [&lt;ulink linkID="1598237" linkType="Reference"&gt;1598237&lt;/ulink&gt;]. In May 2016, the first committee on New drugs of the PAFSC was held by the MHLW and it recommended Orphan Drug designation for selexipag for residual or recurrent CTPH in patients who received or cannot apply surgery  [&lt;ulink linkID="1772083" linkType="Reference"&gt;1772083&lt;/ulink&gt;]. In June 2016, the MHLW granted the drug Orphan Drug status for CTPH [&lt;ulink linkID="1775039" linkType="Reference"&gt;1775039&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In April 2019, Actelion Pharmaceutical was developing the drug as a class 2.4 chemical drug in China [&lt;ulink linkID="2136406" linkType="Reference"&gt;2136406&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  December 2018, the China National Medical Products Administration approved selexipag for the treatment of PAH  to delay disease progression and reduce the risk of hospitalization for PAH [&lt;ulink linkID="2104861" linkType="Reference"&gt;2104861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2018, the product was granted "Clinically Urgent Foreign Drug" in China [&lt;ulink linkID="2089481" linkType="Reference"&gt;2089481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By March 2015, a regulatory submission had been filed in Canada for PAH [&lt;ulink linkID="1638548" linkType="Reference"&gt;1638548&lt;/ulink&gt;]; in January 2016, Health Canada approved selexipag for the long-term treatment of idiopathic PAH, heritable PAH, PAH associated with connective tissue disorders and PAH associated with congenital heart disease, in adult patients with WHO functional class II-III to delay disease progression [&lt;ulink linkID="1729521" linkType="Reference"&gt;1729521&lt;/ulink&gt;]; in June 2016, launch occurred in Canada  [&lt;ulink linkID="1802950" linkType="Reference"&gt;1802950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By September 2018, approval had been granted in Peru [&lt;ulink linkID="2076132" linkType="Reference"&gt;2076132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was approved in Columbia in March 2018 [&lt;ulink linkID="2139882" linkType="Reference"&gt;2139882&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2016, a regulatory filing had been submitted in Brazil for PAH  [&lt;ulink linkID="1788525" linkType="Reference"&gt;1788525&lt;/ulink&gt;]. In January 2018, approval was granted [&lt;ulink linkID="2075639" linkType="Reference"&gt;2075639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In June 2016, a regulatory filing was submitted in Israel for PAH.  In March 2017, the drug was approved in that setting  [&lt;ulink linkID="2075828" linkType="Reference"&gt;2075828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2016, selexipag had been filed for approval in Turkey for PAH  [&lt;ulink linkID="1729521" linkType="Reference"&gt;1729521&lt;/ulink&gt;]; in August 2016, regulatory review was ongoing [&lt;ulink linkID="1788525" linkType="Reference"&gt;1788525&lt;/ulink&gt;]; by September 2018, the drug had been approved in Turkey [&lt;ulink linkID="2075814" linkType="Reference"&gt;2075814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By August 2016, a regulatory filing had been submitted in Singapore for PAH  [&lt;ulink linkID="1788525" linkType="Reference"&gt;1788525&lt;/ulink&gt;]. In November 2017, the product was approved in that country [&lt;ulink linkID="2076165" linkType="Reference"&gt;2076165&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2015, selexipag had been filed for approval in South Korea for PAH [&lt;ulink linkID="1723099" linkType="Reference"&gt;1723099&lt;/ulink&gt;]; in May 2016, the drug was approved in Korea with Orphan designation [&lt;ulink linkID="1773336" linkType="Reference"&gt;1773336&lt;/ulink&gt;], [&lt;ulink linkID="1773327" linkType="Reference"&gt;1773327&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the drug was granted orphan drug designation in Taiwan for primary PAH [&lt;ulink linkID="1941145" linkType="Reference"&gt;1941145&lt;/ulink&gt;], [&lt;ulink linkID="1941147" linkType="Reference"&gt;1941147&lt;/ulink&gt;]. By December 2015, a regulatory filing had been submitted in Taiwan for PAH [&lt;ulink linkID="1723099" linkType="Reference"&gt;1723099&lt;/ulink&gt;]; in February 2018, the product was approved as Uptravi film-coated tablets in Taiwan [&lt;ulink linkID="2010519" linkType="Reference"&gt;2010519&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, the drug had been filed for approval in New Zealand for PAH [&lt;ulink linkID="1622653" linkType="Reference"&gt;1622653&lt;/ulink&gt;]. In March 2016, the Medical Devices Safety Authority approved the drug in New Zealand for that setting [&lt;ulink linkID="1745410" linkType="Reference"&gt;1745410&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, the Australian TGA granted selexipag Orphan status for the treatment of PAH [&lt;ulink linkID="1599346" linkType="Reference"&gt;1599346&lt;/ulink&gt;]. By December 2015, a regulatory filing for PAH had been submitted in Australia [&lt;ulink linkID="1723099" linkType="Reference"&gt;1723099&lt;/ulink&gt;]. In March 2016, the TGA approved the drug in Australia for the treatment of  idiopathic PAH, heritable PAH, PAH associated with connective tissue disease, PAH associated with congenital heart disease with repaired shunts, PAH associated with drugs and toxins, and patients with WHO functional class II, III and IV symptoms [&lt;ulink linkID="1745410" linkType="Reference"&gt;1745410&lt;/ulink&gt;], [&lt;ulink linkID="1750029" linkType="Reference"&gt;1750029&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In January 2017, France's ANSM requested  prescribers not to initiate new treatments with selexipag, pending further investigations into  a number of  deaths reported during initiation of selexipag treatment in France. At that time, the accountability of the drug in the deaths had not been established, but investigations were underway. The ANSM also referred the issue to the European Pharmacovigilance Risk Assessment Committee (PRAC) [&lt;ulink linkID="1907982" linkType="Reference"&gt;1907982&lt;/ulink&gt;]. In February 2017, based on a preliminary review of the five deaths, the PRAC advised that the drug could continue to be used in both existing and new patients but must be used in line with the prescribing information [&lt;ulink linkID="1908239" linkType="Reference"&gt;1908239&lt;/ulink&gt;]. In April 2017, the EMA also advised that the drug could continue to be used with no changes to the prescribing information after  a review concluded that the five patient deaths in France did not suggest an increase in mortality linked to the pulmonary arterial hypertension drug  [&lt;ulink linkID="1916701" linkType="Reference"&gt;1916701&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Chronic thromboembolic  pulmonary hypertension (WHO Group 4)&lt;/subtitle&gt;In April 2019, an IND application was filed  for  in China [&lt;ulink linkID="2136406" linkType="Reference"&gt;2136406&lt;/ulink&gt;]. By April 2019, an implied clinical trial approval was obtained for chronic thromboembolic pulmonary hypertension in China [&lt;ulink linkID="2142223" linkType="Reference"&gt;2142223&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, a randomized, double-blind, placebo-controlled, parallel-group, comparative, phase III study (&lt;ulink linkID="262751" linkType="Protocol"&gt;JapicCTI-163279&lt;/ulink&gt;) commenced to assess the safety and efficacy of NS-304 in Japanese patients (expected n = 72) with CTPH. The primary endpoint was a measure of pulmonary vascular resistance. At that time, the trial was expected to complete in April 2022 [&lt;ulink linkID="1774606" linkType="Reference"&gt;1774606&lt;/ulink&gt;], [&lt;ulink linkID="1775039" linkType="Reference"&gt;1775039&lt;/ulink&gt;]; in July 2018, phase III development in this setting was ongoing in Japan [&lt;ulink linkID="2078735" linkType="Reference"&gt;2078735&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2011, phase II studies had been initiated in Japan for CTPH [&lt;ulink linkID="1233938" linkType="Reference"&gt;1233938&lt;/ulink&gt;]; in May 2015, the trial was ongoing [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pulmonary arterial hypertensionPhase IV&lt;/subtitle&gt;In May 2018, it was reported at the 2018 ATS International Conference in San Diego, CA, that an ongoing, international, randomized, placebo controlled, phase IV study (TRACE, &lt;ulink linkID="290771" linkType="Protocol"&gt;NCT03078907&lt;/ulink&gt;) to assess the effect of selexipag on the daily life of patients with pulmonary arterial hypertension. Primary endpoint was change from baseline to week 24 in actigraphy-assessed DLPA, as measured by: daily time spent in non-sedentary activity, total DLPA per day, total sleep time, wake time after sleep onset, number of awakenings and sleep efficiency; secondary endpoint was change from baseline to week 24 in PAH-SYMPACT domain scores, WHO FC, 6MWD and Borg dyspnea index and N-terminal-pro-b-type natriuretic peptide; and safety and tolerability was monitored [&lt;ulink linkID="2035194" linkType="Reference"&gt;2035194&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, interim data from multicenter, prospective, real-world, US-based, observational registry (SPHERE; SelexiPag: tHe UsErs dRug rEgistry) which evaluated the characteristics and clinical course of pulmonary arterial hypertension patients who transitioned from inhaled, parenteral or oral prostaglandins to selexipag was presented at 2018 ATS International Conference in San Diego, CA. Patients (n = 54) received selexipag therapy from different prostaglandins. In both transitioned and non-transitioned patients, the median time to reach the individual selexipag maintenance was 8.1 weeks. AEs associated with selexipag mode of action including dyspnea, dizziness, fatigue, fluid overload, pneumonia, pulmonary hypertension, aggravated and diarrhea were reported by &amp;gt;/= 5% of patients [&lt;ulink linkID="2035252" linkType="Reference"&gt;2035252&lt;/ulink&gt;]. Further data were presented at same conference. Overall discontinuation of selexipag due to adverse events (AEs) were reported by 36 patients and common AEs lead to discontinuation were aggravated pulmonary hypertension, diarrhea, arthralgia, myalgia, nausea and right ventricular failure. Related to selexipag treatment, at least one AE was reported among 32 patients by investigator with most occurring included diarrhea, headache, myalgia, nausea, arthralgia and jaw pain [&lt;ulink linkID="2035287" linkType="Reference"&gt;2035287&lt;/ulink&gt;]. In September 2018, further data were presented at 28th ERS International Congress in Paris, France. In patients receiving selexipag therapy, the adverse events (AE) deemed by investigator were reported by 32 patients. Among AEs the most common included diarrhea, headache, myalgia, nausea, arthralgia, and jaw pain [&lt;ulink linkID="2072718" linkType="Reference"&gt;2072718&lt;/ulink&gt;]. In April 2019, further data were presented at the 2019 ISHLT Annual Meeting and Scientific Sessions in Orlando, FL. In transitioned (n = 39) versus non-transitioned patients (n = 112) who had baseline and 12-month data, worsened functional class (FC) was observed in 10.3 versus 9.8% patients; stable FC was observed in 69.2 versus 74.1% patients; improved FC was observed in 20.5 versus 16.1% patients, respectively. Selexipag was discontinued in 29 versus 34% transitioned versus non-transitioned patients, with 19.6% in each group discontinued due to adverse events [&lt;ulink linkID="2148008" linkType="Reference"&gt;2148008&lt;/ulink&gt;]. In May 2019, further data of 250 patients were presented at the 2019 ATS International Conference in Dallas, TX. At 6 and 12 months, the median change from baseline in  6-minute walk distance was 8.0 and 16.0 m, respectively; in  brain-type natriuretic peptide (BNP) was -1.0 and 7.0 ng/l, respectively; and in N-terminal prohormone of BNP was -45.0 and -65.0 ng/l, respectively. The proportion of all, newly initiated and previously initiated patients with improved change from baseline to 6 months in WHO functional class (FC) was 21.6, 22.7 and 20.8%, respectively; stable change was 69.0, 70.5 and 68.1%, respectively; and worsened change was 9.5, 6.8 and 11.1%, respectively.[&lt;ulink linkID="2153264" linkType="Reference"&gt;2153264&lt;/ulink&gt;].In May 2019, data of first 250 patients enrolled in SPHERE were presented at the 2019 ATS International Conference in Dallas, TX. Risk assessment was done at baseline and at one year of follow up.A total of 29 patients (11.6%) died, of which 2 (3.4%) from the low-risk group, 19 (11.2%) from the intermediate-risk group and 7(36.85%) from the high-risk group. Overall 196 patients (78% of total population had risk assessment of which 22% had improved, 15% had worsened and 63% had no change in risk group.Of all the patients with available risk assessment data, 85% continued to be in the same risk group (63%) or ameliorated to a less severe risk group (22%).[&lt;ulink linkID="2153014" linkType="Reference"&gt;2153014&lt;/ulink&gt;]    &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pulmonary arterial hypertension (WHO Group 1)&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In April 2019, results from a multicenter, open-label, single-sequence crossover, phase III study which evaluated the safety and tolerability of a temporary switch from a stable dose of oral selexipag to a corresponding iv dose of selexipag in patients (n = 20) with PAH were presented at the 2019 ISHLT Annual Meeting and Scientific Sessions in Orlando, FL. Following both po and iv selexipag dosing, similar exposure to ACT-333679 (active metabolite) was observed: geometric mean ratio (iv/oral) values for AUC(t, ss) was 2.13 and Cmax was 1.98 for selexipag and AUC(t, ss) was 0.80 and Cmax was 0.79 for ACT-333679. In periods 1, 2 and 3 + FU, &amp;gt;/= 1adverse events (AE) were reported by 10, 50 and 40% of patients, respectively. Majority of the patients had mild (40%) and moderate (25%) intensity AEs  [&lt;ulink linkID="2148010" linkType="Reference"&gt;2148010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, information about a prospective, multi-center, open-label, single-group, phase IIIb TRANSIT-1 (&lt;ulink linkID="232067" linkType="Protocol"&gt;NCT02471183&lt;/ulink&gt;) trial in PAH patients  was presented at the 2016 ATS International Conference in San Francisco, CA [&lt;ulink linkID="1767295" linkType="Reference"&gt;1767295&lt;/ulink&gt;]. In May 2017, further efficacy and safety data were presented at the 2017 ATS International Conference in Washington DC. At week-16, 27 patients met all three criteria for sustained treatment transition (ie, not receiving inhaled treprostinil or another prostanoid from week 8, not experiencing selexipag interruptions totaling &amp;gt;/= 8 days, and receiving selexipag at week 16. Headache, diarrhea, jaw pain and dyspnea were the most frequent (&amp;gt;10 patients) adverse events [&lt;ulink linkID="1929679" linkType="Reference"&gt;1929679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a randomized, parallel assigned, double blind, multi-center, placebo-controlled, phase IIIb trial (&lt;ulink linkID="241085" linkType="Protocol"&gt;NCT02558231&lt;/ulink&gt;; AC-065A308, TRITON) was planned in patients (expected n = 144) with newly diagnosed, treatment-naive pulmonary arterial hypertension, to assess the safety and efficacy of an initial triple oral treatment regimen (&lt;ulink linkID="52854" linkType="Drug"&gt;macitentan&lt;/ulink&gt;, &lt;ulink linkID="4119" linkType="Drug"&gt;tadalafil&lt;/ulink&gt; and selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo). At that time, the trial was to complete in December 2018. In September 2016, the study was initiated [&lt;ulink linkID="1775269" linkType="Reference"&gt;1775269&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, a single-arm open-label phase III extension trial (&lt;ulink linkID="65974" linkType="Protocol"&gt;NCT01112306&lt;/ulink&gt;; AC-065A303) began to assess the long-term efficacy and safety in patients (estimated total n = 670, estimated Taiwan n = 13) treated in the GRIPHON study, in the US, Argentina, Australia, Europe, Canada, Chile, China, Colombia, India, Israel, Korea, Malaysia, Mexico, Peru, Russia, Singapore, Taiwan, Thailand, and Turkey. The primary endpoint was the number of participants with adverse events [&lt;ulink linkID="1265512" linkType="Reference"&gt;1265512&lt;/ulink&gt;]. By March 2011, the trial in Taiwan had been completed [&lt;ulink linkID="1953240" linkType="Reference"&gt;1953240&lt;/ulink&gt;]. In November 2016, the completion of the trial was expected in February 2021 [&lt;ulink linkID="1265512" linkType="Reference"&gt;1265512&lt;/ulink&gt;]. In August 2018, data were presented at the 2018 ESC Congress in Munich, Germany. The survival rate for patients who received selexipag from the start was 72.6% at 60 months, versus 64.9% in patients who changed from placebo to selexipag, and 75.7% in patients who received selexipag in the GRIPHON study as well as in the OLE. The observed safety profile was consistent with the known safety profile of selexipag [&lt;ulink linkID="2065689" linkType="Reference"&gt;2065689&lt;/ulink&gt;], [&lt;ulink linkID="2067196" linkType="Reference"&gt;2067196&lt;/ulink&gt;]. In September 2018, further clinical data were presented at the 28th ERS International Congress in Paris, France. Irrespective of the number of low-risk criteria at baseline, selexipag decreased the risk of disease progression. At follow-up, the treatment effect was found to be increased with the number of low-risk criteria. Selexipag treated patients were more likely to improve their risk profile [&lt;ulink linkID="2072844" linkType="Reference"&gt;2072844&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a phase III trial with a morbidity/mortality endpoint was planned [&lt;ulink linkID="1026449" linkType="Reference"&gt;1026449&lt;/ulink&gt;]. The double-blind, placebo-controlled, phase III morbidity/mortality study (&lt;ulink linkID="65727" linkType="Protocol"&gt;NCT01106014&lt;/ulink&gt;; GRIPHON; AC-065A302) in patients with PAH (total n = 1156, estimated Taiwan n = 13) was initiated in December 2009 and would be conducted in the US, Argentina, Australia, Europe, Canada, Chile, China, Colombia, India, Israel, Korea, Malaysia, Mexico, Peru, Russia, Singapore, Taiwan, Thailand, Turkey and the Ukraine. The primary endpoint was time to clinical worsening following twice daily dosing for up to 3.5 years, and secondary measures included the 6-min walk distance test and Borg dyspnea index [&lt;ulink linkID="1076237" linkType="Reference"&gt;1076237&lt;/ulink&gt;], [&lt;ulink linkID="1076071" linkType="Reference"&gt;1076071&lt;/ulink&gt;], [&lt;ulink linkID="1265482" linkType="Reference"&gt;1265482&lt;/ulink&gt;], [&lt;ulink linkID="1953241" linkType="Reference"&gt;1953241&lt;/ulink&gt;]. By December 2012, 	more than 1000 patients had been enrolled [&lt;ulink linkID="1391187" linkType="Reference"&gt;1391187&lt;/ulink&gt;]. In May 2013, Actelion reported that an interim analysis for efficacy and futility had been completed and an independent  DMC had recommended the trial to continue with no modifications to study design or procedures; at that time, 1143 patients had been recruited [&lt;ulink linkID="1416847" linkType="Reference"&gt;1416847&lt;/ulink&gt;]. Later in May 2013, enrollment was completed with a total of 1156 patients. The trial was conducted under an SPA agreement with the FDA [&lt;ulink linkID="1523100" linkType="Reference"&gt;1523100&lt;/ulink&gt;], [&lt;ulink linkID="1570046" linkType="Reference"&gt;1570046&lt;/ulink&gt;]. In February 2014, the trial met the total number of primary endpoint events to complete the study [&lt;ulink linkID="1547852" linkType="Reference"&gt;1547852&lt;/ulink&gt;]. In June 2014, topline data from the study were reported. Patients were treated for up to 4.3 years, and selexipag reduced the risk of a morbidity/mortality event by 39% compared with placebo; the efficacy was consistent across the key subgroups including age, gender, WHO Functional Class, PAH etiology and background PAH therapy. The overall tolerability profile of selexipag was consistent with prostacyclin therapies [&lt;ulink linkID="1570046" linkType="Reference"&gt;1570046&lt;/ulink&gt;].   In October 2014, the trial was completed [&lt;ulink linkID="1265482" linkType="Reference"&gt;1265482&lt;/ulink&gt;]. In March 2015, similar long-term data   were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA  [&lt;ulink linkID="1641935" linkType="Reference"&gt;1641935&lt;/ulink&gt;], [&lt;ulink linkID="1647943" linkType="Reference"&gt;1647943&lt;/ulink&gt;].  In April 2015, similar  data were presented at the 35th ISHLT Annual Meeting held in Nice, France [&lt;ulink linkID="1659454" linkType="Reference"&gt;1659454&lt;/ulink&gt;].  In May 2015, similar clinical data were presented at the 2015 ATS International Conference in Denver, CO [&lt;ulink linkID="1679501" linkType="Reference"&gt;1679501&lt;/ulink&gt;]. In August 2015, data from the trial were presented at the 2015 ESC Congress in London, UK. At month 36, the time from randomization to the first occurrence of a morbidity or mortality event up to end of treatment (primary endpoint) was 43, 42, 34, and 37% in patients who had received no PAH therapy, phosphodiesterase type 5 inhibitor (PDE-5i) monotherapy, endothelin receptor antagonist (ERA) monotherapy, and ERA + PDE-5i combination, respectively. Data demonstrated that selexipag exhibited a consistent effect on long-term outcome in patients with no therapy and previous PAH monotherapy or dual combination therapy [&lt;ulink linkID="1691118" linkType="Reference"&gt;1691118&lt;/ulink&gt;].  In September 2015, further results were presented at the 25th ERS Congress in Amsterdam, the Netherlands. Selexipag treatment effect was consistent across prespecified subgroups of background PAH treatment (ERA monotherapy, PDE5i monotherapy, ERA + PDE5i, no PAH therapy) [&lt;ulink linkID="1700131" linkType="Reference"&gt;1700131&lt;/ulink&gt;]. In October 2015, clinical data were presented at the 2015 CHEST Annual Meeting in Montreal, Canada. The risk of a morbidity/mortality event (primary endpoint) was found to be consistent by selexipag across dose groups with hazard ratios versus overall placebo was 0.60, 0.53 and 0.64 in the low, medium and high-dose groups, respectively [&lt;ulink linkID="1725839" linkType="Reference"&gt;1725839&lt;/ulink&gt;]. These data were published in December 2015 [&lt;ulink linkID="1723605" linkType="Reference"&gt;1723605&lt;/ulink&gt;], [&lt;ulink linkID="1745602" linkType="Reference"&gt;1745602&lt;/ulink&gt;], [&lt;ulink linkID="1745410" linkType="Reference"&gt;1745410&lt;/ulink&gt;]. In March 2016, further data were reported; mean treatment duration in selexipag-treated patients was 76.4  versus 71.2 weeks for placebo patients [&lt;ulink linkID="1745410" linkType="Reference"&gt;1745410&lt;/ulink&gt;]. In May 2016, further clinical data were presented at the 2016 ATS International Conference in San Francisco, CA. Across all the PAH-CTD subgroups, the treatment effect was consistent. Targeting the prostacyclin pathway with selexipag was found to be therapeutically effective [&lt;ulink linkID="1767274" linkType="Reference"&gt;1767274&lt;/ulink&gt;]. In August 2016, results from an analysis of associated with congenital heart disease (PAH-CHD) patients (n = 110) with congenital cardiac shunts at least one year after correction were presented at the 2016 ESC Congress in Rome, Italy. A primary endpoint event was observed in 13 patients in the selexipag group and in 9 patients in the placebo group at the completion of study treatment. The risk of the primary outcome composite of morbidity/mortality was decreased by 42% in the selexipag group, which was consistent with the overall treatment effect [&lt;ulink linkID="1792438" linkType="Reference"&gt;1792438&lt;/ulink&gt;]. In September 2016, further results were presented at the 26th ERS International Congress in London, UK. Overall, 19% of patients in the selexipag group reported treatment interruptions during a median duration of 70.7 weeks. Most frequent reasons for selexipag treatment interruptions were PGI2- and non-PGI2-related adverse events [&lt;ulink linkID="1793695" linkType="Reference"&gt;1793695&lt;/ulink&gt;].  In May 2019, post hoc analysis data were presented at the 2019 ATS International Conference in Dallas, TX. Among selexipag treated patients, the risk of morbidity/mortality (primary composite endpoint) was reduced in both groups, those treated earlier with a hazard ratio (HR) of 0.45 compared with those treated later with a HR of 0.70 (p = 0.0391); and remained consistent in both groups after adjusting the baseline covariates (HR, 0.47 versus 0.74; p = 0.301). Moreover, results were consistent with overall GRIPHON population (HR, 0.63); those had no PAH therapy at baseline and PAH therapy at baseline (HR, 0.55 and 0.65, respectively); those had PAH therapy at baseline and time from diagnosis at &amp;lt;/= 6 months and &amp;gt; 6 months (HR, 0.47 and 0.73, respectively) and no PAH therapy at baseline and time from diagnosis at &amp;lt;/= 6 months and &amp;gt; 6 months (HR, 0.45 and 1.02, respectively) [&lt;ulink linkID="2153074" linkType="Reference"&gt;2153074&lt;/ulink&gt;], [&lt;ulink linkID="2153445" linkType="Reference"&gt;2153445&lt;/ulink&gt;], [&lt;ulink linkID="2153678" linkType="Reference"&gt;2153678&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Sarcoidosis-associated Pulmonary Hypertension (SAPH)&lt;/subtitle&gt;In May 2019, a multi-center, 52-week,  randomized, double-blind, sequentially-assigned, placebo-controlled,   followed by a 104-week, single-arm, open-label phase II/III trial (&lt;ulink linkID="379711" linkType="Protocol"&gt;NCT03942211&lt;/ulink&gt;; AC-065D301; 2018-004887-74)  to assess the efficacy and safety of  selexipag in patients (expected n = 150)  with sarcoidosis-associated pulmonary hypertension (SAPH) was to begin in August 2019. The primary endpoint was to determine the pulmonary vascular resistance (PVR) at peak concentration at Week 20. At that time, the trial was expected to complete in February, 2025  [&lt;ulink linkID="2150908" linkType="Reference"&gt;2150908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2018, a prospective, multicenter, open-label, single-arm, phase II study (&lt;ulink linkID="335819" linkType="Protocol"&gt;NCT03492177&lt;/ulink&gt;; AC-065A203) was  to be initiated    to  investigate the safety, tolerability and pharmacokinetics of selexipag in children (expected n = 55) with pulmonary arterial hypertension. The primary endpoint was to measure area under the plasma concentration-time curve over a dose interval at steady state of selexipag and its metabolite ACT-333679 combined and to know the body weight dependence of  dose-exposure relationship for pediatric patients. At that time, the study was expected to complete in November 2025 [&lt;ulink linkID="2025983" linkType="Reference"&gt;2025983&lt;/ulink&gt;]; in July 2018, the trial was initiated and was expected to complete in December 2025 [&lt;ulink linkID="2025983" linkType="Reference"&gt;2025983&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2011, phase II studies had been initiated in Japan for PAH  [&lt;ulink linkID="1198272" linkType="Reference"&gt;1198272&lt;/ulink&gt;]. By January 2016, the trial conducted jointly by Nippon Shinyaku and Actelion had  shown  significant improvement in pulmonary hemodynamics in patients undergoing selexipag treatment [&lt;ulink linkID="1726726" linkType="Reference"&gt;1726726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2009, a phase IIa trial had completed enrollment [&lt;ulink linkID="985274" linkType="Reference"&gt;985274&lt;/ulink&gt;]. In July 2009, the multicenter, double-blind, randomized, placebo-controlled study completed and results were reported. The trial assessed the efficacy and safety of selexipag in 43 PAH patients who were randomized 3:1. The study met its primary outcome measure of change from baseline in pulmonary vascular resistance (PVR) with high statistical significance. The drug was well tolerated [&lt;ulink linkID="1026449" linkType="Reference"&gt;1026449&lt;/ulink&gt;]. In May 2010, full data were presented at the American Thoracic Society congress in New Orleans, LA. There was a significant 30.3% reduction in PVR after 17 weeks of treatment. There was also an 'encouraging' numerical improvement in 6-min walk distance  [&lt;ulink linkID="1100455" linkType="Reference"&gt;1100455&lt;/ulink&gt;]. In September 2010, similar data were presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain [&lt;ulink linkID="1134341" linkType="Reference"&gt;1134341&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, preparations for phase II trials were underway [&lt;ulink linkID="819701" linkType="Reference"&gt;819701&lt;/ulink&gt;]. By November 2007, phase II trials for pulmonary hypertension had begun in Europe [&lt;ulink linkID="860460" linkType="Reference"&gt;860460&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, clinical data from a single-center, open-label study which evaluated the absolute bio-availability of an oral (tablet) versus iv formulation of selexipag in 19 healthy male subjects were presented at the 2016 Annual Meeting of the ACCP in Bethesda, MD. Subjects in pilot phase (preceded the main study; n = 3) received single 20 min iv infusion of selexipag (50 g). Subjects in main study (randomized, two-way crossover, single-dose; n = 16) received single, po dose of 400 g selexipag or a single 80 min iv infusion of 200 g selexipag. A total of 18 subjects completed the study and one subject in the main phase withdrew consent prematurely. The absolute po bioavailability was found to be 49.4%. Following iv administration of selexipag, geometric mean total body clearance was 18 l/h and volume of distribution was 12 l. Exposure to ACT-333679 was 3.4- and 1.3-fold higher than to selexipag following po and iv administration, respectively. Selexipag administered as either po or iv was well tolerated [&lt;ulink linkID="1894943" linkType="Reference"&gt;1894943&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Raynauds disease&lt;/subtitle&gt;In October 2014, a double-blind, randomized, parallel-assigned, phase II trial (&lt;ulink linkID="213070" linkType="Protocol"&gt;NCT02260557&lt;/ulink&gt;; AC-065C202) to evaluate selexipag in subjects (expected n = 70) with Raynaud's phenomenon secondary to systemic sclerosis was planned to be initiated in France, Germany and the UK. At that time, the trial was expected to complete in May 2015; later, in October 2014, the trial was initiated in the UK and France [&lt;ulink linkID="1601898" linkType="Reference"&gt;1601898&lt;/ulink&gt;]. By July 2015, efficacy data had been obtained that did not support further pursuit of that indication [&lt;ulink linkID="1679169" linkType="Reference"&gt;1679169&lt;/ulink&gt;]. In June 2016, clinical data were presented from a multi-center, placebo-controlled trial at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Patients (n = 74) were randomized to receive selexipag (200 to 1600 microg bid) or placebo bid in single blind run-in period. Decrease in average number of Raynaud's phenomenon  attacks was observed per week in both treatment groups during maintenance phase (primary efficacy endpoint). Mean change in Raynaud's phenomenon attacks duration was +2.7 and +4.6 min in selexipag and placebo groups, respectively. Overall, &amp;gt;/= 1 adverse events  were reported by all patients in selexipag group and 86.8% of patients in placebo group  [&lt;ulink linkID="1767906" linkType="Reference"&gt;1767906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Arteriosclerosis obliterans&lt;/subtitle&gt; In September 2016, the drug was in phase III development for arteriosclerosis obliterans [&lt;ulink linkID="1795871" linkType="Reference"&gt;1795871&lt;/ulink&gt;]; in July  2018, the drug was listed as being in phase II development for arteriosclerosis obliterans [&lt;ulink linkID="2075572" linkType="Reference"&gt;2075572&lt;/ulink&gt;], [&lt;ulink linkID="2078735" linkType="Reference"&gt;2078735&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By May 2015, Nippon Shinyaky had started a phase II trial in patients with arteriosclerosis obliterans [&lt;ulink linkID="1661496" linkType="Reference"&gt;1661496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spinal stenosis&lt;/subtitle&gt;In February 2018,  a randomized, placebo-controlled,  double-blind, multi-center, exploratory phase II study (&lt;ulink linkID="333008" linkType="Protocol"&gt;JapicCTI-183866&lt;/ulink&gt;)   was initiated in Japan to assess the     efficacy of NS-304 in patients (expected n = 120) with lumbar spinal canal stenosis with intermittent claudication. The primary endpoint was the amount of change from walking possible distance from baseline. At that time, the trial was expected to complete in August 2019  [&lt;ulink linkID="2018730" linkType="Reference"&gt;2018730&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In March 2018, a clinical trial application was filed in China; in September 2018, the application was granted Priority Review [&lt;ulink linkID="2071090" linkType="Reference"&gt;2071090&lt;/ulink&gt;]. In November 2018, another clinical trial application was filed in China [&lt;ulink linkID="2089040" linkType="Reference"&gt;2089040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, data from an open-label, randomized, two-treatment, two-period, crossover study which evaluated the effect of gemfibrozil on the pharmacokinetics of selexipag and its active metabolite (ACT-333679), in healthy male subjects, were presented at the 13th EACPT Congress in Prague, Czech Republic. Subjects (n = 20) received selexipag (400 microg) alone (arm A) or after multiple-dose gemfibrozil (600 mg bid; arm B). In the presence of multiple-dose gemfibrozil, selexipag exposure was increased by 2-fold (geometric mean ratio [arm B/arm A] for Cmax was 1.39 and for AUC(0 to infinity) was 1.96). In addition, ACT-333679 exposure was increased by 11-fold (geometric mean ratio [arm B/arm A] for Cmax was 3.63 and for AUC(0 to infinity) was 11.09). Headache (90.0%), nausea (75.0%) and vomiting (60.0%) were the frequently reported adverse  events [&lt;ulink linkID="2004003" linkType="Reference"&gt;2004003&lt;/ulink&gt;]. Further data of the effect of rifampicin on the pharmacokinetics of selexipag (n = 20) were presented at the same conference. Concomitant administration of selexipag and multiple-dose rifampicin resulted in no relevant change in selexipag exposure (geometric mean ratio [arm B/arm A] for Cmax was 1.76, and for AUC(0 to infinity) was 1.25), whereas exposure to ACT-333679 was decreased by half (geometric mean ratio [arm B/arm A] for Cmax was 1.30 and for AUC(0 to infinity) was 0.51). All AEs were of mild or moderate in intensity [&lt;ulink linkID="2004010" linkType="Reference"&gt;2004010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, a randomized, open-label, two-way crossover assigned, single-center, phase I trial (&lt;ulink linkID="258773" linkType="Protocol"&gt;NCT02745860&lt;/ulink&gt;; AC-065-112) was planned in Germany in May 2016 in healthy volunteers (expected n = 20) to compare the pharmacokinetics of Selexipag following single oral administration of four film-coated pediatric tablets of 50 versus 200 microg. The trial was expected to complete in July 2016. In June 2016, the study was initiated [&lt;ulink linkID="1755751" linkType="Reference"&gt;1755751&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, data  presented at the 2014 ACCP Annual Meeting in Atlanta, GA, from a phase I study of the bioequivalence of selexipag administered as 1600 mg bid over 4.5 days as either a single 1600 microg dose or 8 X 200 microg doses, showed bioequivalence with either administration [&lt;ulink linkID="1597167" linkType="Reference"&gt;1597167&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, data from a prospective, single center, open-label, crossover, phase I trial were presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in Atlanta, GA. Subjects (n = 20) were randomized to receive selexipag (400 microg po) in arm 1 and lopinavir/ritonavir (400/100 mg bid) +  selexipag in arm 2. The respective Cmax, t1/2, AUC (0 to infinity) and Tmax values were 4.71 ng/ml, 1.60 h, 10.68 ng.h/ml and 1.00 h in arm 1; 9.75 ng/ml, 2.34 h, 23.87 ng.h/ml and 1.00 h in arm 2 for selexipag. The respective values were 5.61 ng/ml, 9.80 h, 31.01 ng.h/ml and 2.00 h in arm 1; 7.45 ng/ml, 6.35 h, 33.35 ng.h/ml and 2.00 h in arm 2 for ACT-333679. Treatments were well tolerated [&lt;ulink linkID="1535860" linkType="Reference"&gt;1535860&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2011, data were presented from a  single-center, randomized, placebo-controlled, double-blind, multiple-period, phase I study in healthy males   (n = 16) at 112th Annual Meeting of the ASCPT in Dallas, TX.  Multiple doses up to 1600 microg were well tolerated and the MTD was 1600 microg  [&lt;ulink linkID="1174680" linkType="Reference"&gt;1174680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, data were presented from a  phase I, single-center, double-blind, randomized, placebo-controlled, multiple ascending dose (200 microg, 400 microg and up-titration scheme from 400 to 600 microg) study  in healthy  subjects   (n = 24) at 112th Annual Meeting of the ASCPT in Dallas, TX.  After bid administration of 200 to 600 microg selexipag under fed conditions, there was no indication of time-dependent changes in the pharmacokinetics of selexipag or its active metabolite, ACT-333679, and the rate and extent of exposure to selexipag and ACT-333679 at steady state showed an approximate dose proportionality.  Selexipag was well tolerated at doses up to 600 microg [&lt;ulink linkID="1174704" linkType="Reference"&gt;1174704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, phase I trials of selexipag began in Japan [&lt;ulink linkID="904513" linkType="Reference"&gt;904513&lt;/ulink&gt;]. By July 2009, phase I trials had been completed [&lt;ulink linkID="1026449" linkType="Reference"&gt;1026449&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2005, clinical data were presented at the 2005 AHA meeting in Dallas, TX. Selexipag (0.001 to 10 ng/ml) was orally administered to healthy male volunteers (n = 5) in a microdose pharmacokinetic study. Selexipag was converted into MRE-269 which had a long plasma elimination half-life (7.9 h). Plasma levels of MRE-269 remained at 25% of peak levels for over 8 h [&lt;ulink linkID="634927" linkType="Reference"&gt;634927&lt;/ulink&gt;], [&lt;ulink linkID="633392" linkType="Reference"&gt;633392&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;​In May 2018, in vitro data were presented at 2018 ATS International Conference in San Diego, CA. In human lung fibroblast cells, ACT-333679 treatment attenuated TGF-beta1-mediated fibrotic response. ACT-333679 inhibited gene expression of two essential mediators of fibrosis YAP/TAZ [&lt;ulink linkID="2035295" linkType="Reference"&gt;2035295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, in vivo data were presented at the 2017 ATS International Conference in Washington DC. In Sugen-hypoxia induced pulmonary arterial hypertension rats, selexipag ameliorated the remodeling of lung vessel and prostacyclin pathway gene expression [&lt;ulink linkID="1929600" linkType="Reference"&gt;1929600&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2016, preclinical data were presented at the 2016 ATS International Conference in San Francisco, CA. At the IP receptor, ACT-333679 and selexipag showed EC50 values of 14 and 680 nM, respectively [&lt;ulink linkID="1767153" linkType="Reference"&gt;1767153&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. At the IP receptor, ACT-333679 showed corresponding potencies were EC50 values of 352, 277, 120 and 29 nM, respectively. The concentration of the selexipag, ACT-333679 needed to elicit cAP response depended on cellular IP receptor expression levels with higher receptor levels required low drug concentrations and vice versa [&lt;ulink linkID="1767325" linkType="Reference"&gt;1767325&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In November 2015, preclinical data were presented at the AHA's Scientific Sessions 2015 in Orlando, FL. CAY-10441 (1 microM) did not inhibit relaxation to ACT-333679 when added prior to ACT-333679 (pEC50 5.6 ; not statistically significant versus control), but CAY-10441 (0.1 to 10 microM) reversed relaxation of EPA when added after sub-maximal relaxation to ACT-333679 (1 microM) was reached (relaxation 48.8 % of PGF2alpha contraction) [&lt;ulink linkID="1713544" linkType="Reference"&gt;1713544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA. Overall, ACT-333679 retained full efficacy in inducing cAMP responses and did not lead to prostacyclin receptor desensitization and internalization like the classical prostacyclin analogs [&lt;ulink linkID="1647917" linkType="Reference"&gt;1647917&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference showing that repeated po administration or continuous iv infusion  of selexipag decreased mean arterial BP without any development of tachyphylaxis in conscious spontaneously hypertensive rats implanted with telemetry recording systems [&lt;ulink linkID="1645819" linkType="Reference"&gt;1645819&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 24th ERS Annual Congress in Munich, Germany. In HEK–hIP cells, ACT-333679 potently activated adenylate cyclase (EC50 = 6.1 nM). In pulmonary arterial smooth muscle (PASM) cells, ACT-333679 induced phosphorylation of MLCK and Hsp20 (EC50 = 4.2 nM) and plasma membrane potential hyperpolarization (EC50 = 32 nM). ACT-333679 induced PASMC relaxation (EC50 = approximately 4.3 nM). In PDGF-BB-stimulated PASMC cells, ACT-333679 showed anti-proliferative activity (EC50 = 2.9 nM) [&lt;ulink linkID="1592081" linkType="Reference"&gt;1592081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were reported at the Inflammation 2010 meeting in Stevenage, UK demonstrating selexipag to elicit a vasodilatory effect on rat pulmonary artery and to be effective on both normal and diseased arterial tissue. The drug also demonstrated a plasma half-life of 4.4 h and was highly effective in monocrotaline-induced PAH rats and significantly improved survival [&lt;ulink linkID="1153687" linkType="Reference"&gt;1153687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, data were published showing that selexipag, with its high selectivity for the PGI2 receptor, did not contract rat gastric fundus in vitro, unlike iloprost and &lt;ulink linkID="5943" linkType="Drug"&gt;beraprost&lt;/ulink&gt;. In vivo in rats, selexipag did not significantly alter gastric function, unlike beraprost which slowed gastrointestinal transport. It was suggested that selexipag's selectivity may minimize gastric side effects [1208530]&lt;/para&gt;&lt;para&gt;In November 2005, data were presented at the 2005 AHA meeting in Dallas, TX. Oral administration of selexipag (1 mg/kg) to rats increased femoral skin blood flow for over 4 h without affecting heart rate. Plasma elimination half-life was 4.4 h. In monocrotaline-induced pulmonary hypertensive rats, selexipag reduced right ventricular systolic pressure and hypertrophy. Continuous vasodilation produced by selexipag was not attenuated by chronic treatment. In radioligand binding assays MRE-269 was observed to selectively bind to PGI2 over other human prostanoid receptors [&lt;ulink linkID="634927" linkType="Reference"&gt;634927&lt;/ulink&gt;], [&lt;ulink linkID="633392" linkType="Reference"&gt;633392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, preclinical data on MRE-269 and selexipag were presented at the Pharmaceutical Sciences World Congress in Kyoto, Japan. MRE-269 bound to the non-prostanoid prostacyclin (PGI2) receptor with a Ki value of 12 nM and increased cAMP levels in Chinese hamster ovary cells expressing the PGI2 receptor. The Ki values of MRE-269 for prostaglandin E2 and thromboxane A2 were at least 330-fold higher than for the PGI2 receptor. The prodrug, selexipag, demonstrated a Ki value for the PGI2 receptor that was 40-fold higher than that of MRE-269. Platelet aggregation in humans and monkeys was inhibited at concentrations &amp;lt; 10 microM of MRE-269. After oral administration of selexipag, plasma concentrations of MRE-269 were maintained near the peak level for &amp;gt; 10 h in rats and dogs and &amp;gt; 24 h in monkeys. Only rat plasma had the ability to hydrolyze selexipag to MRE-269. Plasma concentrations were negligible in rats, but present in dogs and monkeys. Selexipag at 1 mg/kg maintained an increase in femoral skin blood flow for &amp;gt; 4 h in rats without affecting blood pressure and heart rate. When compared to &lt;ulink linkID="5943" linkType="Drug"&gt;beraprost&lt;/ulink&gt;, selexipag significantly increased blood flow for a longer period and exhibited a higher maximum effect [&lt;ulink linkID="541566" linkType="Reference"&gt;541566&lt;/ulink&gt;]. In August 2004, similar data on selexipag and its active metabolite were presented at the 18th International Symposium on Medicinal Chemistry in Copenhagen, Denmark and Malmo, Sweden [&lt;ulink linkID="552370" linkType="Reference"&gt;552370&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2011, the Pediatric Committee (PDCO) of the EMA adopted a positive opinion on  Actelion's pediatric investigation plan (PIP) for the drug for cardiovascular diseases [&lt;ulink linkID="1224391" linkType="Reference"&gt;1224391&lt;/ulink&gt;]. In May 2013, the Pediatric Committee (PDCO) adopted a positive opinion on modification to the agreed PIP for treatment of PAH [&lt;ulink linkID="1430558" linkType="Reference"&gt;1430558&lt;/ulink&gt;]. In March 2019, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of pulmonary arterial hypertension [&lt;ulink linkID="2138426" linkType="Reference"&gt;2138426&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Sabina Antonela Antoniu, University of Medicine and Pharmacy, Iasi, Romania&lt;/para&gt;&lt;para&gt;Submission date: 19 October 201&lt;br/&gt;Publication date: 22 November 2011&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease characterized by an increased pressure in the pulmonary artery, which is a result of vasoconstriction, thrombosis and vascular remodeling. In PAH, prostacyclin activity is impaired as a result of, for example, endothelial dysfunction. Available treatments for PAH include the synthetic prostacyclin &lt;ulink linkType="Drug" linkID="6132"&gt;epoprostenol&lt;/ulink&gt; and prostacyclin analogs, such as &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;. These have improved the disease outcome of patients with PAH, but are short-acting, thus requiring frequent dosing. &lt;ulink linkType="Company" linkID="23780"&gt;Actelion&lt;/ulink&gt;, under license from &lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt;, is developing the novel non-prostanoid prostacyclin receptor agonist selexipag (formerly known as NS-304 and ACT-293987), which is an oral parent drug that is hydrolyzed to the active form ACT-333679 (formerly known as MRE-269). In preclinical studies, selexipag and ACT-333679 were both highly selective for the prostacyclin receptor, and a longer half-life of ACT-333679, compared with prostacyclin and its analogs, has been observed in animals and healthy volunteers. In a phase II, proof-of-concept clinical trial in patients with PAH, selexipag improved hemodynamic parameters compared with placebo. At the time of publication, patients with PAH were being recruited to a phase III trial of selexipag and results should provide valuable information about the likely success of selexipag. Additionally, selexipag was being assessed in patients with chronic thromboembolic pulmonary hypertension.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease of abnormally high blood pressure in the arteries of the lung, and is defined by a mean pulmonary artery pressure &amp;gt; 25 mmHg at rest and by an increased pulmonary vascular resistance, which can lead to right heart failure and death [&lt;ulink linkType="Reference" linkID="1232009"&gt;1232009&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232128"&gt;1232128&lt;/ulink&gt;]. From a pathogenic point of view, PAH is characterized by a triad of processes occurring in the small pulmonary arteries; these are vasoconstriction, thrombosis, and vascular remodeling caused by the hyperproliferation of the smooth muscle fibers, increased collagen deposition and inflammation [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232011"&gt;1232011&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232013"&gt;1232013&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232128"&gt;1232128&lt;/ulink&gt;]. There are several subsets of PAH, including idiopathic PAH, heritable PAH, PAH associated with HIV infection, PAH associated with connective tissue diseases, and PAH induced by drugs and toxins. PAH is not caused by lung disease or left heart disease, and is one of the clinical groups of the more generally termed pulmonary hypertension, the current classification of which is divided into five categories: (i) PAH; (ii) pulmonary hypertension resulting from left heart disease, including pulmonary venous hypertension; (iii) pulmonary hypertension associated with lung diseases and/or hypoxemia; (iv) pulmonary hypertension resulting from (thrombo)embolic diseases; and (v) pulmonary hypertension with unclear multifactorial mechanisms [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232011"&gt;1232011&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232013"&gt;1232013&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232128"&gt;1232128&lt;/ulink&gt;]. The various presentations of pulmonary hypertension are estimated to affect up to 100 million people worldwide [&lt;ulink linkType="Reference" linkID="1232128"&gt;1232128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;PAH presents with symptoms that are common to a range of other diseases, such as shortness of breath, dizziness and fainting, which are exacerbated by exercise. PAH is usually diagnosed with right heart catheterization following suspicion based on clinical and routine diagnostic tests as well as on a relevant personal history (eg, occurrence in relatives) [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;]. Several pathways are currently believed to be involved in the development with PAH and several targeted therapies have concomitantly been developed [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232013"&gt;1232013&lt;/ulink&gt;]. These pathways include the overproduction of the vasoconstrictor endothelin-1 of the endothelin system [&lt;ulink linkType="Reference" linkID="243961"&gt;243961&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232183"&gt;1232183&lt;/ulink&gt;], and the reduction in the vasodilators nitric oxide (NO; of the NO/cyclic guanosine monophosphate [cGMP] pathway) [&lt;ulink linkType="Reference" linkID="1232202"&gt;1232202&lt;/ulink&gt;] or prostacyclin (PGI2; of the PGI2 pathway) [&lt;ulink linkType="Reference" linkID="1232205"&gt;1232205&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232208"&gt;1232208&lt;/ulink&gt;]. The endothelin system is targeted by endothelin receptor antagonists, such as &lt;ulink linkType="Drug" linkID="5871"&gt;bosentan&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt;, while the NO/cGMP pathway is targeted by inhibitors of phosphodiesterase type 5 (PDE5; the enzyme degrading cGMP) by, for example, &lt;ulink linkType="Drug" linkID="8713"&gt;sildenafil&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4119"&gt;tadalafil&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="21994"&gt;vardenafil&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232013"&gt;1232013&lt;/ulink&gt;]. Several drugs also target the PGI2 pathway and therapy with the synthetic PGI2 &lt;ulink linkType="Drug" linkID="6132"&gt;epoprostenol&lt;/ulink&gt; was first developed in the 1990s, demonstrating marked improvements in exercise tolerance and survival in patients with PAH [&lt;ulink linkType="Reference" linkID="1232017"&gt;1232017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;PGI2 is an arachidonic acid metabolite with potent vasodilator and anti-aggregant (by counteracting the actions of thromboxane A2) properties, which is produced mainly by cells of the vascular endothelium [&lt;ulink linkType="Reference" linkID="1232305"&gt;1232305&lt;/ulink&gt;]. PGI2 exerts its effects via the PGI2 (IP) receptor [&lt;ulink linkType="Reference" linkID="1232303"&gt;1232303&lt;/ulink&gt;], which is present in lung, heart, thymus, kidney and spleen tissues [&lt;ulink linkType="Reference" linkID="1232304"&gt;1232304&lt;/ulink&gt;]. The IP receptor contributes to the maintenance of homeostasis and other processes, such as the regulation of tissue blow flow, inhibition of thrombus formation, protection of vascular endothelial cells and inhibition of smooth muscle cell proliferation [&lt;ulink linkType="Reference" linkID="367634"&gt;367634&lt;/ulink&gt;]. Thus, the endothelial dysfunction, which is present in PAH from its early stages, explains the PGI2 deficit, which favors vasoconstriction, smooth muscle proliferation and thrombosis [&lt;ulink linkType="Reference" linkID="367634"&gt;367634&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232015"&gt;1232015&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The use of &lt;ulink linkType="Drug" linkID="6132"&gt;epoprostenol&lt;/ulink&gt; has been beneficial to patients with PAH; however, PGI2 has a very short half-life (3 to 5 min) [&lt;ulink linkType="Reference" linkID="1232305"&gt;1232305&lt;/ulink&gt;] requiring continuous infusions of &lt;ulink linkType="Drug" linkID="6132"&gt;epoprostenol&lt;/ulink&gt; to the patient, which is not only inconvenient but also increases the risk of side effects, such as catheter-related sepsis [&lt;ulink linkType="Reference" linkID="1232015"&gt;1232015&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232017"&gt;1232017&lt;/ulink&gt;]. Several PGI2 analogs were subsequently developed, such as the inhaled &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt;, the injectable &lt;ulink linkType="Drug" linkID="20137"&gt;treprostinil&lt;/ulink&gt; and the oral &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;, which have longer half-lives, but still require frequent dosing [&lt;ulink linkType="Reference" linkID="1232010"&gt;1232010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232013"&gt;1232013&lt;/ulink&gt;]. Furthermore, these compounds are not selective for the IP receptor and structural similarities of the PGI2 analogs with other prostaglandins, such as prostaglandin E or D, or thromboxane A2, mean that these compounds also stimulate the receptors of these other arachidonic acid metabolites, which results in several side effects, such as abdominal cramping, gastric pain, nausea, vomiting, diarrhea and gastric irritation [&lt;ulink linkType="Reference" linkID="1232324"&gt;1232324&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232326"&gt;1232326&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232333"&gt;1232333&lt;/ulink&gt;]. Therefore, non-prostanoid IP receptor agonists with a longer duration of action and a better safety profile are currently being investigated.&lt;/para&gt;&lt;para&gt;One such agent is selexipag (formerly known as NS-304 and ACT-293987), which is being developed by &lt;ulink linkType="Company" linkID="23780"&gt;Actelion&lt;/ulink&gt;, under license from &lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt;, for the potential treatment of PAH [&lt;ulink linkType="Reference" linkID="898522"&gt;898522&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232346"&gt;1232346&lt;/ulink&gt;]. Selexipag is an oral, long-acting, non-prostanoid IP receptor agonist parent drug of the active form ACT-333679 (formerly known as MRE-269), which was highly selective for the IP receptor in preclinical studies [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;]. In a phase II, proof-of-concept clinical trial (ClinicalTrials.gov identifier: &lt;ulink linkType="Protocol" linkID="61171"&gt;NCT00993408&lt;/ulink&gt;) in patients with PAH, selexipag improved hemodynamic parameters compared with placebo [&lt;ulink linkType="Reference" linkID="1180990"&gt;1180990&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209873"&gt;1209873&lt;/ulink&gt;]. At the time of publication, patients with PAH were being recruited to a phase III trial (&lt;ulink linkType="Protocol" linkID="65727"&gt;NCT01106014&lt;/ulink&gt;) of selexipag. Additionally, selexipag was being assessed in patients with chronic thromboembolic pulmonary hypertension [&lt;ulink linkType="Reference" linkID="1233938"&gt;1233938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The active compound ACT-333679 ([4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid) was identified following screening of a panel of platelet aggregation inhibitors [&lt;ulink linkType="Reference" linkID="552370"&gt;552370&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;] on the basis of the chemical structures of non-prostanoid-type IP receptor agonists, such as &lt;ulink linkType="Drug" linkID="5409"&gt;BMY-42393&lt;/ulink&gt; and octimibate, which are structurally very different from PGI2, except for the carboxylic acid moiety [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;]. An initial 2-amino-5,6-diphenylpyrazine lead discovered from SAR studies had a different side chain and had a piperazine ring instead of an oxazole or imidazole ring present in &lt;ulink linkType="Drug" linkID="5409"&gt;BMY-42393&lt;/ulink&gt; and octimibate, respectively. The lead compound moderately inhibited human platelet aggregation (IC50 = 1.5 microM). Optimization of the lead compound demonstrated that the linker length between the diphenylated heterocycle and the carboxylic acid moiety as well as the presence of the concatenating nitrogen atom adjacent to the pyrazine ring was critical to anti-aggregatory activity. A hexamethylene linker, instead of the heptamethylene linker in the initial lead, was determined to be the optimal length and addition of an oxygen atom in the beta position of the carboxylic acid group in the linker as well as replacement of the N-methyl group of the lead compound with small-sized alkyl groups led to well-tolerated compounds with enhanced activity (IC50 for platelet aggregation &amp;lt; 1 microM) [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;]. Studies on selectivity for the IP receptor and pharmacokinetics identified ACT-333679 as the most promising candidate [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;] and ACT-333679 was selected for further studies (relevant results discussed in the 'Preclinical development' and 'Metabolism and pharmacokinetics' sections) [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;SAR studies of drug development have demonstrated that N-acylsulfonamides or N-acylureas were good carboxylic acid surrogates and can also act as parent drugs. In order to improve the pharmacokinetic properties of ACT-333679, including potential side effects (headache, hypotension and nausea) that could be caused by rapid and temporary increases in plasma concentration, and to increase the half-life, studies led to the development of the parent drug selexipag ([2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]) [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209876"&gt;1209876&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA169602"&gt;WO-02088084&lt;/ulink&gt;]. Selexipag is an N-acylsulfonamide derivative of the carboxylic acid of ACT-333679, which, when hydrolyzed, yields ACT-333679 (selexipag-derived carboxylic acid) [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;]. In vivo and in vitro, selexipag undergoes slow hydrolysis, leading to sustained production of ACT-333679 (discussed in the 'Metabolism and pharmacokinetics' section). This slow release increases the half-life of selexipag (and ACT-333679) and reduces or prevents adverse effects associated with PGI2 agonists, which led &lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt; to focus their efforts on the development of the parent drug rather than the metabolite [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Selexipag was synthesized by condensing 5-chloro-2,3-diphenylpyrazine and 4-(isopropylamino)butan-1-ol, followed by transformation of the hydroxy group of the intermediate pyrazine-aminobutanol to the acetic acid derivative, and conversion of the acid group to the corresponding acylsulfonamide [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA169602"&gt;WO-02088084&lt;/ulink&gt;]. The starting 5-chloropyrazine was prepared by reacting benzyl and glycinamide hydrochloride in the presence of aqueous sodium hydroxide in methanol, and then treatment with phosphoryl chloride and a catalytic amount of sulfuric acid. The starting aminobutanol was synthesized via reductive amination of acetone with 4-aminobutanol. A mixture of 5-chloro-2,3-diphenylpyrazine and 4-(isopropylamino)butan-1-ol was heated at 190degC to give 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butan-1-ol. The butanol moiety was converted to a tert-butyl acetate derivative with tert-butyl bromoacetate under phase-transfer conditions. The acetate was hydrolyzed with methanolic sodium hydroxide and the acid obtained was coupled with methanesulfonamide via activation with 1,1'-carbonyldiimidazole to produce the target N-acylsulfonamide (selexipag) [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA169602"&gt;WO-02088084&lt;/ulink&gt;]. Information about different salts and crystalline forms were given in &lt;ulink linkType="Patent" linkID="PA6364973"&gt;WO-2011024874&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6295710"&gt;WO-2010150865&lt;/ulink&gt;, respectively.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;The affinities for the IP receptor of selexipag and ACT-333679, as well as &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt;, were assessed in the CHO cell line [&lt;ulink linkType="Reference" linkID="541566"&gt;541566&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. Before being exposed to the IP receptor agonists, CHO cells were transfected with either rat or human IP receptor genes to produce rIP-CHO and hIP-CHO cell lines, respectively. The affinities of selexipag, ACT-333679 and &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; for the IP receptor were evaluated with the agonist-binding displacement method using radiolabeled &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt;. Radiolabeled &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; itself had a binding affinity (Kd) of 4.07 nM for the human IP receptor in hIP-CHO cells and 7.95 nM for the rat IP receptor in rIP-CHO cells. Selexipag, ACT-333679 and &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; concentration-dependently inhibited the binding of radiolabeled &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; in both hIP-CHO and rIP-CHO cells with Ki values for the human IP receptor of 260, 20 and 39 nM, respectively, and for the rat IP receptor of 2100, 220 and 19 nM, respectively. No specific binding to the IP receptor was detected in untransfected CHO cells [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Activation of the IP receptor results in increases in intracellular cAMP levels [&lt;ulink linkType="Reference" linkID="1233522"&gt;1233522&lt;/ulink&gt;] and increases in cytosolic Ca2+ concentrations [&lt;ulink linkType="Reference" linkID="1233523"&gt;1233523&lt;/ulink&gt;]. In hIP-CHO cells, intracellular levels of cAMP were increased concentration-dependently by selexipag, ACT-333679, &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; with EC50 values of 177.0, 11.5, 9.4 and 2.0 nM, respectively. Only &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; increased intracellular levels of Ca2+ in hIP-CHO cells [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Receptor selectivity profiles of selexipag and ACT-333679 were determined in binding assays for the human prostaglandin D receptor, prostaglandin E (EP) receptors 1, 2, 3 and 4, the prostaglandin F receptor, and the thromboxane A2 receptor [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;]. The Ki values of selexipag for all receptors were &amp;gt; 10 microM and of ACT-333679 were 2.6, 5.8, and 4.9 microM for prostaglandin D, EP2 and EP4, respectively, and &amp;gt; 10 microM for the other receptors. In contrast, &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; had a Ki value for the EP3 receptor of 680 nM and also demonstrated agonism at this receptor (EC50 = 750 nM) [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Inhibition of platelet aggregation was assessed by exposing platelet-rich human and monkey plasma to selexipag and ACT-333679 [&lt;ulink linkType="Reference" linkID="541566"&gt;541566&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. Selexipag inhibited platelet aggregation in platelet-rich plasma from humans and monkeys with IC50 values of 5.5 and 3.4 microM, respectively; the IC50 for ACT-333679 was 0.21 microM in both plasmas. ACT-333679 also inhibited platelet aggregation in platelet-rich plasma from dogs and rats with IC50 values of 25 and 10 microM, respectively, while selexipag did not exhibit an anti-aggregant activity on dog plasma (IC50 &amp;gt; 100 microM; rat plasma was not tested because of rapid hydrolysis of selexipag to ACT-333679 in rat plasma) [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo and ex vivo&lt;/subtitle&gt;The efficacy of selexipag (0.3, 1 and 3 mg/kg) to increase skin blood flow was assessed by measuring femoral skin blood flow (FSBF) in anesthetized rats administered selexipag intraduodenally [&lt;ulink linkType="Reference" linkID="541566"&gt;541566&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. FSBF was dose-dependently increased for &amp;gt; 4 h at 1 and 3 mg/kg of selexipag (p &amp;lt; 0.01 versus vehicle), with a maximal increase of 93% in FSBF relative to vehicle at 1 h post-dose of 3 mg/kg of selexipag (p &amp;lt; 0.01) and a maximal increase of 43% in FSBF relative to vehicle at 2 h post-dose of 1 mg/kg of selexipag (p &amp;lt; 0.01). The 0.3-mg/kg dose of selexipag exhibited no significant augmenting effect on FSBF. In comparison, &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (0.03, 0.1 and 0.3 mg/kg) was administered intraduodenally to anesthetized rats and, at the highest 0.3-mg/kg dose of &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;, FSBF was increased for ~ 2 h with the maximum effect being a 43% increase in FSBF relative to vehicle (p &amp;lt; 0.01). No increase in FSBF was observed with 0.1 and 0.03 mg/kg of &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effects of selexipag (1 and 3 mg/kg intraduodenally) on the heart rate and mean arterial pressure were assessed in anesthetized rats [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. At 3 mg/kg of selexipag (the dose associated with a 93% increase in FSBF), the heart rate was increased by ~ 10% relative to vehicle, but mean arterial pressure was not affected. At the 1-mg/kg dose of selexipag, which also significantly increased FSBF, no effect on the heart rate and mean arterial pressure was observed. In contrast, the 0.3-mg/kg dose of &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;, which augmented FSBF by 43%, increased the heart rate by 47% and decreased mean arterial pressure by 26% [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Desensitization of the IP receptor following repeat administration of selexipag was evaluated in rats pretreated with oral selexipag (3 mg/kg bid) for 1, 2, 3 or 4 weeks prior to intraduodenal administration of selexipag (3 mg/kg) under anesthetic. Administration of the intraduodenal dose of selexipag resulted in significant increases in FSBF relative to vehicle in all rats, regardless of the pretreatment length (no p-value specified). Maximal increases in FSBF in selexipag-treated rats ranged from ~ 70 to 90% relative to vehicle and increases were sustained for ~ 4 h [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effect of selexipag on vasodilation of the pulmonary artery was assessed by measuring the relaxant response to ACh in right main pulmonary arterial rings isolated from rats [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1231985"&gt;1231985&lt;/ulink&gt;]. The arterial rings of 3 to 4 mm in length were isolated and precontracted with 10 microM of prostaglandin F2alpha, and then treated with ACh. The relaxant response to ACh was measured and expressed as a percentage of that induced by 100 microM of the vasodilator papaverine. In arterial rings from healthy rats, ACh (10 microM to 300 microM) concentration-dependently induced vasodilation of the pulmonary artery with relaxation of up to 81% of that induced by papaverine at ~ 0.3 mM of ACh. When pulmonary hypertension was induced by the alkaloid monocrotaline (MCT; 40 mg/kg sc), the relaxant response to ACh was markedly attenuated with a maximal relaxation of 25% of that induced by papaverine at ~ 0.3 mM of ACh. However, in arterial rings taken from MCT-treated rats subsequently treated with selexipag (1 mg/kg po, bid for 19 days), the deterioration of the relaxant response induced by MCT was suppressed and a maximal relaxation of 50% of that induced by papaverine was observed at ~ 0.3 mM of ACh (p &amp;lt; 0.05 for selexipag in MCT-treated versus only MCT-treated rats). Assessment of hypertrophy of the pulmonary arterial wall of these rats demonstrated that arterial wall thickness was 16.2% (calculated from [{medial wall thickness x 2}/external diameter] x 100) in healthy rats, 32.2% in MCT-treated rats and 23.5% in MCT-treated rats subsequently administered selexipag [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Furthermore, right ventricular hypertrophy and right ventricular systolic pressure were measured in healthy rats, MCT-treated rats and MCT-treated rats subsequently administered selexipag (protocol as in previous paragraph) as well as in MCT-treated rats subsequently administered &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (0.1 mg/kg po, bid for 19 days) [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;]. Right ventricular hypertrophy was quantified with the ratio of the right ventricle weight to the left ventricle plus septum weights and this ratio was significantly higher in the MCT-treated rats (0.500) compared with healthy rats (0.279, p &amp;lt; 0.01). Selexipag significantly reduced this ratio compared with only MCT-treated rats (0.380, p &amp;lt; 0.01), whereas the effect with &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (0.441) was not significant. Right ventricular systolic pressure was significantly lower in both selexipag- and &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;-treated rats compared with MCT-treated rats. Right ventricular systolic pressures in healthy rats, MCT-treated rats, and MCT-treated rats subsequently administered selexipag or &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; were 36, 68, 51 and 57 mm Hg, respectively (p &amp;lt; 0.01 for selexipag in MCT-treated versus only MCT-treated rats, p &amp;lt; 0.05 for &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; in MCT-treated versus only MCT-treated rats). The heart rate was not significantly different among the groups [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Relaxant and contractile responses to ACT-333679 (1 nM to 30 microM), &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; (both at 0.1 nM to 30 microM) were evaluated in large pulmonary arteries (LPAs) with or without endothelium (LPA+ and LPA-, respectively) and small pulmonary arteries without endothelium (SPA-), which had been isolated from rats [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;]. Arterial rings from these arteries were precontracted with 10 microM of prostaglandin F2alpha before being exposed to the IP receptor agonists. At the end of the experiment, 100 microM of papaverine was added to produce maximal relaxation, and relaxation induced by the IP receptor agonists was expressed as a percentage of that induced by papaverine. ACT-333679 induced consistent concentration-dependent vasodilation in LPA+, LPA- and SPA- with maximal relaxations of 86, 78 and 80%, respectively, of that induced by papaverine at ~ 30 microM of ACT-333679. In contrast, vasodilation induced by &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; was less in SPA- (maximal relaxation of 21.5 and ~ 64.0%, respectively) than in LPA+ (81.3 and ~ 82.0%, respectively) and LPA- (55.3 and ~ 70%, respectively) [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a subsequent experiment, the EP3 receptor agonist sulprostone (0.1 nM to 1 microM) induced concentration-dependent vasoconstriction in all three artery subtypes, with the effect on SPA- being significantly greater than in LPA+ and LPA- (p &amp;lt; 0.01). Addition of the EP3 receptor antagonist DBTSA ((2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide; 3 microM) attenuated the sulprostone-induced vasoconstriction in SPA-. When DBTSA (3 microM) was assessed on ACT-333679 (1 nM to 30 microM)-induced vasodilation, no significant effect on the concentration-response curve for ACT-333679-induced vasodilation was observed. On the contrary, the &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;- and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; (both at 0.1 nM to 30 microM)-induced vasodilation in LPA- was significantly enhanced by the addition of DBTSA (p &amp;lt; 0.01 and p &amp;lt; 0.05, respectively), indicating that the vasodilation in SPA- induced by &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; was counteracted by EP3 receptor agonism [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additionally, the effect of sulprostone (0.1 nM to 1 microM), ACT-333679 (1 nM to 30 microM), &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; (both at 0.1 nM to 30 microM) on vasoconstriction was assessed in LPA+ isolated from healthy and MCT-treated rats. In LPA+ from healthy rats, vasoconstriction was induced by sulprostone and by concentrations &amp;gt; 1 microM of &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt;; this effect was augmented in LPA+ from MCT-treated rats. In contrast, ACT-333679 induced no vasoconstriction in LPA+ from healthy or MCT-treated rats. Moreover, &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;- and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt;-induced vasodilation was more strongly attenuated in LPA+ from MCT-treated rats compared with healthy rats (p &amp;lt; 0.01), while ACT-333679 induced similar vasodilation in LPA+ from MCT-treated and healthy rats [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Furthermore, in a survival study, rats received a single dose of MCT (60 mg/kg sc) and subsequently vehicle or selexipag (1 mg/kg bid) for 45 days. Assessment of the 45-day survival rate of MCT-treated rats receiving vehicle and MCT-treated rats subsequently administered selexipag demonstrated survival rates of 33 and 73%, respectively (p = 0.0307) [&lt;ulink linkType="Reference" linkID="940132"&gt;940132&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1231985"&gt;1231985&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;A study was performed in order to evaluate if selexipag was associated with gastrointestinal side effects, which are known to occur as a result of the EP3 receptor agonism observed with other IP receptor agonists, such as &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1208530"&gt;1208530&lt;/ulink&gt;]. The contraction of gastric rat fundus in response to selexipag and ACT-333679 was compared with &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="20137"&gt;treprostinil&lt;/ulink&gt;. Neither selexipag nor ACT-333679 (both at 10 nM to 1 mM) contracted rat fundal strips above baseline force, even at the highest concentration, while a concentration-dependent contraction of rat fundal strips was induced by &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (from 1 to 100 microM) and &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; (from 0.01 to 10 microM), and also at the highest concentration of &lt;ulink linkType="Drug" linkID="20137"&gt;treprostinil&lt;/ulink&gt; (100 microM). Addition of DBTSA (10 microM) significantly inhibited the contraction induced by &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (p &amp;lt; 0.05), &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; (p &amp;lt; 0.01) and &lt;ulink linkType="Drug" linkID="20137"&gt;treprostinil&lt;/ulink&gt; (p &amp;lt; 0.05) [&lt;ulink linkType="Reference" linkID="1208530"&gt;1208530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo, administration of selexipag (1 and 3 mg/kg po) did not affect intestinal transport or gastric emptying. Although a low dose of &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt; (0.03 mg/kg po) also had no effect, a higher dose (0.1 mg/kg po) significantly slowed intestinal transport and gastric emptying (p &amp;lt; 0.05) [&lt;ulink linkType="Reference" linkID="1208530"&gt;1208530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;Following intravenous administration of ACT-333679 to rats (3 mg/kg), the half-life of ACT-333679 was 4.9 h and the AUC was 5.2 microg.h/ml [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;]. Similar experiments in dogs (1 mg/kg) produced a half-life of 5.9 h and an AUC of 72.5 microg.h/ml. When oral ACT-333679 (10, 3 and 1 mg/kg) was administered to rats, dogs and monkeys, respectively, ACT-333679 had an extended duration of action (compared with PGI2) with half-lives of 3.6, 6.2 and 5.6 h, respectively. The maximal concentration of ACT-333679 in rats (1.9 microg/ml), dogs (14.9 microg/ml) and monkeys (0.11 microg/ml) was achieved after 0.8, 0.8 and 2.3 h, respectively, and respective AUC values were 17.7, 176.0 and 0.65 microg.h/ml. In rats and dogs, oral bioavailability of ACT-333679 was 102 and 80%, respectively [&lt;ulink linkType="Reference" linkID="848630"&gt;848630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The hydrolysis of selexipag to ACT-333679 was assessed in hepatic microsomes and in plasma from rats, dogs, monkeys and humans [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;]. The hydrolysis rates in hepatic microsomes for the respective species were 0.090, 0.030, 0.057 and 0.019 nmol/min/mg protein. In rat plasma, the hydrolysis rate was 0.5 nmol/min/ml, but no measurable hydrolysis was detected in the other plasmas. These results suggested that selexipag can be converted to the carboxylic acid (ACT-333679) in vivo. Assessment of the esterase responsible for hydrolysis using a serine hydrolase inhibitor (phenylmethylsulfonyl fluoride; 100 microM) demonstrated that the hepatic enzyme responsible for hydrolysis was possibly carboxylesterase [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The in vivo hydrolysis of oral selexipag (1 mg/kg) to ACT-333679 was also assessed in monkeys [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;]. Following administration of selexipag, ACT-333679 was detected in monkey plasma, which was indicative of hydrolysis taking place. The half-lives of selexipag and ACT-333679 were 4.9 and 10.7 h, respectively, demonstrating a ~ 2-fold increase in the half-life of ACT-333679 following parent drug administration compared with direct ACT-333679 administration. The Cmax of selexipag (47 ng/ml) and ACT-333679 (35 ng/ml) was reached after 6.7 and 14.0 h, respectively, and the AUC values were 384 and 859 ng.h/ml, respectively. The Cmax value of selexipag-derived ACT-333679 was lower than that after direct administration of ACT-333679 (35 versus 110 ng/ml), which was believed to be a result of slow hydrolysis of selexipag to ACT-333679. The investigators reported that this may reduce the risk of side effects associated with the rapid and temporary increase in plasma concentration related to the administration of IP receptor agonists [&lt;ulink linkType="Reference" linkID="883243"&gt;883243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo pharmacokinetic studies were also performed in rats and dogs administered an oral dose of selexipag (10 and 3 mg/kg, respectively) [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. Selexipag was rapidly hydrolyzed to ACT-333679, which was detectable in the plasma of both species within minutes of dosing. In rats, ACT-333679 had a Tmax of 1.3 h, a Cmax of 1.1 microg/ml, a half-life of 4.4 h and an AUC0-infinity of 11.6 microg.h/ml (values for selexipag could not be obtained because of its rapid hydrolysis to ACT-333679). In dogs, selexipag had a Tmax of 0.8 h, a Cmax of 7.6 microg/ml, a half-life of 1.8 h and an AUC0-infinity of 15.0 microg.h/ml, while the respective values for ACT-333679 were 3.3 h, 9.0 microg/ml, 7.1 h and 116.0 microg.h/ml [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A microdose pharmacokinetic study was performed in healthy Caucasian males (n = 5) who received a single dose of selexipag (100 microg po) [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;]. Selexipag peaked rapidly and was quickly hydrolyzed to ACT-333679, which was detected in the plasma 15 min after selexipag administration. Selexipag had a Tmax of 0.7 h, a Cmax of 4.1 ng/ml, a half-life of 1.7 h and an AUC0-infinity of 5.8 ng.h/ml. For ACT-333679, the respective values were 2.0 h, 2 ng/ml, 7.9 h and 13.4 ng.h/ml [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I clinical trial assessed single doses of selexipag (100 to 800 microg po) in healthy volunteers (n = 52) [&lt;ulink linkType="Reference" linkID="1135524"&gt;1135524&lt;/ulink&gt;]. Selexipag was administered to sequential groups of 8 volunteers (6 on selexipag and 2 on placebo). A further group of 12 volunteers received selexipag (400 microg po) in the fasted state and, following a 7-day wash-out period, after a high-fat meal. Selexipag was rapidly hydrolyzed to ACT-333679 with Tmax values of 1.3 h (1.0 to 1.3 h) and 2.8 h (2.2 to 2.8 h) for selexipag and ACT-333679, respectively. The respective half-lives were 0.7 to 2.5 and 9.4 to 12.7 h. The exposure to ACT-333679 was decreased by 27% in the presence of food [&lt;ulink linkType="Reference" linkID="1135524"&gt;1135524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I, double-blind, randomized, placebo-controlled, up-titrating, single-center clinical trial, the pharmacokinetics of multiple doses of oral selexipag (200, 400 and up-titration from 400 to 600 microg) were assessed in three groups of healthy volunteers (n = 8/group; 6 on selexipag and 2 on placebo) [&lt;ulink linkType="Reference" linkID="1174704"&gt;1174704&lt;/ulink&gt;]. Overall, the Tmax of selexipag was reached at ~ 2 h and of ACT-333679 at ~ 4 h, and steady-state was reached on day 8. The half-lives of selexipag and ACT-333679 ranged from 1.2 to 1.4 and 10.8 to 14.5 h, respectively. Following administration of selexipag under fed conditions, no time-dependent changes in the pharmacokinetics of selexipag and ACT-333679 were observed. The AUC of both selexipag and ACT-333679 increased dose-proportionally and no accumulation was noted. Analysis of the 400- to 600-microg up-titration group revealed a Cmax of 5.47 ng/ml, a Tmax of 2 h and a half-life of 1.35 h for selexipag; the respective values for ACT-333679 were 8.83 ng/ml, 4 h and 10.82 h. There was no selexipag detected in urine, while the dose fraction excreted as ACT-333679 was &amp;lt; 0.1%. On day 1, the mean renal clearance for the 200- and 400-microg doses was 3.90 and 4.68 ml/h, respectively, and on day 8, the mean renal clearance for the 200-, 400- and 600-microg doses was 6.53, 9.84 and 9.44 ml/h, respectively [&lt;ulink linkType="Reference" linkID="1174704"&gt;1174704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A further phase I, double-blind, randomized, placebo-controlled, multiple-ascending-dose, up-titrating, single-center clinical trial assessed the pharmacokinetics of oral selexipag (400 microg bid for 3 days, up-titrated with 200-microg bid steps q3d up to 1800 microg bid) in healthy male volunteers (n = 16; 12 on selexipag and 4 on placebo) [&lt;ulink linkType="Reference" linkID="1174680"&gt;1174680&lt;/ulink&gt;]. At the 1600-microg twice-daily dose of selexipag, Tmax values were 2 h for selexipag and 4 h for ACT-333679. The respective half-lives of selexipag and ACT-333679 at the 1800-microg twice-daily dose of selexipag were 1.4 and 8.7 h. The Cmax and AUC0-infinity values of selexipag and ACT-333679 increased approximately dose-proportionally, and the mean exposure to ACT-333679 was ~ 4-fold greater than that of selexipag. No accumulation of selexipag or ACT-333679 was observed during the 3-day administration period for each dose [&lt;ulink linkType="Reference" linkID="1174680"&gt;1174680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Selexipag was assessed in four phase I clinical trials in healthy volunteers, two evaluating single doses of selexipag [&lt;ulink linkType="Reference" linkID="633392"&gt;633392&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1135524"&gt;1135524&lt;/ulink&gt;] and two evaluating multiple, up-titration doses of selexipag [&lt;ulink linkType="Reference" linkID="1174680"&gt;1174680&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1174704"&gt;1174704&lt;/ulink&gt;]. These trials assessed the pharmacokinetics and safety of selexipag, and available results are reported in the 'Metabolism and pharmacokinetics' and 'Side effects and contraindications' sections, respectively.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II, proof-of-concept, double-blind, randomized, placebo-controlled, up-titration, parallel-group-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="61171"&gt;NCT00993408&lt;/ulink&gt;, NS-304/-02) assessed oral selexipag (200 microg bid, up-titrated to 400, 600 and 800-microg bid on days 3, 7 and 21) in patients (n = 43; aged &gt;/= 18 years) with PAH [&lt;ulink linkType="Reference" linkID="1180990"&gt;1180990&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209873"&gt;1209873&lt;/ulink&gt;]. Eligible patients had to have symptomatic PAH, a pulmonary vascular resistance (PVR) &amp;gt; 400 dynes.s/cm5 and, if their exercise capacity was measured, a 6-min walking distance (6MWD) between 150 to 500 m. Patients also had to be under stable doses of endothelin receptor antagonists and/or PDE5 inhibitors during a 12-week screening period prior to the trial start; no PGI2 or prostanoid derivatives were allowed in eligible patients. Patients were randomized in a 3:1 ratio to either selexipag (n = 33) or placebo (n = 10) for 17 weeks. The primary efficacy endpoint was the change from baseline to week 17 in the PVR, expressed as a percentage of the baseline value. Secondary endpoints included the change from baseline in the 6MWD, right heart hemodynamic parameters and change from baseline in plasma N-terminal proB-type natriuretic peptide (NT-proBNP; precursor of BNP, a neurohormone released in response to hemodynamic stress and increased in patients with heart failure). The 17-week trial period was completed by 31 patients receiving selexipag and 9 patients receiving placebo; of the selexipag-treated patients, 14 (45.2%) were up-titrated to the maximum dose of 800 microg twice-daily of selexipag. At baseline, the mean PVR was 928.6 and 867.2 dynes.s/cm5 in the selexipag and placebo groups, respectively. At 17 weeks, a significant reduction in PVR was observed in selexipag-treated patients, with a placebo-corrected reduction of 30.3% (p = 0.0045) in the per-protocol analysis (n = 29 on selexipag and 6 on placebo) and a placebo-corrected reduction of 33% (p = 0.0022) in the intention-to-treat analysis (n = 32 on selexipag and 10 on placebo). The mean baseline 6MWD was 394.7 and 350.3 m in the selexipag and placebo groups, respectively. At 17 weeks, selexipag improved the 6MWD (+ 24.7 m) compared with placebo (+ 0.4 m). At baseline, the NT-proBNP levels were 1601.35 and 2400.94 pg/ml in the selexipag and placebo groups, respectively. A placebo-corrected reduction of 212.83 pg/ml was achieved in selexipag-treated patients at 17 weeks. Assessment of hemodynamic effects at 17 weeks relative to baseline demonstrated an improvement in the cardiac index (placebo-corrected increase of 0.48 l/min/m2), a reduction in pulmonary arterial pressure (placebo-corrected decrease of 7.4 mmHg), and increases in the right atrial pressure (placebo-corrected increase of 3.2 mmHg) and pulmonary capillary wedge pressure (placebo-corrected increase of 2.2 mmHg) [&lt;ulink linkType="Reference" linkID="1180990"&gt;1180990&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209873"&gt;1209873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II clinical trials of selexipag in patients with PAH and chronic thromboembolic pulmonary hypertension had been initiated in Japan at the time of publication [&lt;ulink linkType="Reference" linkID="1198272"&gt;1198272&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1233938"&gt;1233938&lt;/ulink&gt;]. Further details were not available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;At the time of publication, a phase III, double-blind, randomized, placebo-controlled, parallel-group-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="65727"&gt;NCT01106014&lt;/ulink&gt;, AC-065A302, GRIPHON) was recruiting patients (expected n = 670; aged 18 to 75 years) with symptomatic PAH to assess the efficacy and safety of selexipag (po, bid). The primary endpoint was the time to the first clinical worsening of PAH over an observation period of up to 3.5 years. Secondary endpoints included the effects of selexipag on 6MWD and NT-proBNP. Results were expected in 2013 [&lt;ulink linkType="Reference" linkID="1209032"&gt;1209032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additionally, a phase III, long-term extension, open-label, single-group-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="65974"&gt;NCT01112306&lt;/ulink&gt;, AC-065A303) was planned to enroll patients (expected n = 670) with PAH who had participated in the GRIPHON trial. The safety and tolerability of selexipag (po, bid) were to be assessed during the open-label extension.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In the microdose pharmacokinetic study in five volunteers, selexipag was well tolerated. There were five adverse events, including two headaches, in four volunteers, which were all considered to be mild in intensity. No physiologically significant changes in blood pressure, heart rate, body temperature, clinical laboratory tests or physical examinations were observed [&lt;ulink linkType="Reference" linkID="838076"&gt;838076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I clinical trial assessing single doses of selexipag in healthy volunteers, doses up to 400 microg of selexipag were well tolerated and the most common adverse event was headache. At the 600- and 800-microg doses, nausea, dizziness and vomiting also occurred in addition to headache. There were no treatment-related effects on vital signs, clinical laboratory and ECG parameters [&lt;ulink linkType="Reference" linkID="1135524"&gt;1135524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I, multiple-dose clinical trial, up-titration up to 600 microg of selexipag was well tolerated. Overall, 66 treatment-emergent adverse events were observed in 20 volunteers. All adverse events were mild or moderate in intensity, and the most common adverse event was headache. There were no clinically significant effects on vital signs, clinical laboratory and ECG parameters [&lt;ulink linkType="Reference" linkID="1174704"&gt;1174704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the other phase I, up-titration clinical trial, up-titration up to 1600 microg twice-daily of selexipag was well tolerated [&lt;ulink linkType="Reference" linkID="1174680"&gt;1174680&lt;/ulink&gt;]. At the maximum dose of 1800 microg twice-daily of selexipag, the incidence of adverse events requiring concomitant medication was increased. Overall, four patients receiving selexipag at 400, 600, 1000 and 1800 microg twice-daily and one patient receiving placebo discontinued from the trial because of adverse events. There were no deaths or serious adverse events. The most common adverse events included headache (91.7%) in both placebo and selexipag groups, and nausea (66.7%), pain in the jaw (66.7%), myalgia (66.7%) and arthralgia (58.3%) in selexipag-treated volunteers. There were no clinically significant changes in laboratory parameters, vital signs, ECG or physical examinations, and there were also no effects on platelet aggregation, blood coagulation or bone turnover markers [&lt;ulink linkType="Reference" linkID="1174680"&gt;1174680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II, proof-of-concept clinical trial, selexipag was generally well tolerated [&lt;ulink linkType="Reference" linkID="1180990"&gt;1180990&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209873"&gt;1209873&lt;/ulink&gt;]. There were 31 (93.9%) and 10 (100%) patients in the selexipag and placebo groups, respectively, experiencing &gt;/= 1 adverse event, and serious adverse events were observed in 6 (18.2%) and 4 (40%) patients in the respective groups. No deaths occurred during the trial period. In both groups, the most common adverse event was headache (66.7 and 20% for selexipag and placebo, respectively). Selexipag-related adverse events most commonly included pain in the jaw (36.4%), pain in the extremity (30.3%) and nausea (27.3%), none of which were observed in the placebo group. Adverse events were most frequent in the up-titration period (0 to 27 days; eg, pain in the extremity = 30.3%) and decreased over time (eg, pain in the extremity for 28 to 55, 56 to 83 and &gt;/= 84 days was 28.1, 28.1 and 12.9%, respectively) [&lt;ulink linkType="Reference" linkID="1180990"&gt;1180990&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1209873"&gt;1209873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;Selexipag was first claimed in &lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt;'s &lt;ulink linkType="Patent" linkID="PA169602"&gt;WO-02088084&lt;/ulink&gt;, which was licensed to Actelion  for its development and commercialization. The application claims heterocyclic derivatives as IP receptor agonists useful for the treatment, amongst others, of vascular disorders, hypertension, arteriosclerosis, thrombotic disorders, diabetic nephropathy, allergies and bronchial asthma. Selexipag was specifically claimed as compound 32 in claim 14 and disclosed in example 84 on page 88. ACT-333679 is also disclosed in this filing as compound 3 in claim 14 and example 42 on page 72. &lt;ulink linkType="Patent" linkID="PA169602"&gt;WO-02088084&lt;/ulink&gt; has been granted in the US as &lt;ulink linkType="Patent" linkID="PA2982938"&gt;US-07205302&lt;/ulink&gt;, Europe as &lt;ulink linkType="Patent" linkID="PA3316304"&gt;EP-01400518&lt;/ulink&gt; and Japan as &lt;ulink linkType="Patent" linkID="PA5644583"&gt;JP-04479152&lt;/ulink&gt;, as well as most other territories. Most of the regional family members expire in April 2022 except for the US patent, which expires in April 2023 following US154 extension.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt; has also claimed several new uses for selexipag and ACT-333679. &lt;ulink linkType="Patent" linkID="PA5364515"&gt;WO-2009107736&lt;/ulink&gt; claims their use as fibrosis inhibitors useful for treating a range of indications, including tubulointerstitial nephritis, cirrhosis, chronic pancreatitis, gastric cancer, cystic fibrosis, rheumatoid arthritis, prostatomegaly, Alzheimer's disease and type I diabetes. &lt;ulink linkType="Patent" linkID="PA5462957"&gt;WO-2009154246&lt;/ulink&gt; claims their use in erectile dysfunction, &lt;ulink linkType="Patent" linkID="PA5467727"&gt;WO-2009157396&lt;/ulink&gt; claims their use in spinal canal stenosis, &lt;ulink linkType="Patent" linkID="PA5467728"&gt;WO-2009157397&lt;/ulink&gt; claims their use in NSAID-associated intestinal tract injury and &lt;ulink linkType="Patent" linkID="PA5467729"&gt;WO-2009157398&lt;/ulink&gt; claims their use in inflammatory bowel diseases. &lt;ulink linkType="Patent" linkID="PA5364515"&gt;WO-2009107736&lt;/ulink&gt; has been filed as &lt;ulink linkType="Patent" linkID="PA6322083"&gt;US-20110015211&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6244584"&gt;EP-02246336&lt;/ulink&gt; in the US and Europe, respectively, &lt;ulink linkType="Patent" linkID="PA5467727"&gt;WO-2009157396&lt;/ulink&gt; as &lt;ulink linkType="Patent" linkID="PA6433641"&gt;US-20110105518&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6378291"&gt;EP-02292231&lt;/ulink&gt;, respectively, and &lt;ulink linkType="Patent" linkID="PA5467729"&gt;WO-2009157398&lt;/ulink&gt; as &lt;ulink linkType="Patent" linkID="PA6447222"&gt;US-20110118254&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6365734"&gt;EP-02289518&lt;/ulink&gt;, respectively. However, none of these regional filings had been granted at the time of publication.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt; has also claimed crystalline forms of selexipag in &lt;ulink linkType="Patent" linkID="PA6295710"&gt;WO-2010150865&lt;/ulink&gt;, with the corresponding Argentinian filing &lt;ulink linkType="Patent" linkID="PA6588285"&gt;AR-00077242&lt;/ulink&gt; assigned to Actelion, and base-addition salts (including potassium, sodium, tert-butylamine and dimethylaminoethanol) of selexipag are claimed in &lt;ulink linkType="Patent" linkID="PA6364973"&gt;WO-2011024874&lt;/ulink&gt;. Neither application had national or regional equivalents at the time of publication&lt;/para&gt;&lt;para&gt;In addition, in &lt;ulink linkType="Patent" linkID="PA5511945"&gt;WO-2010018549&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="23780"&gt;Actelion&lt;/ulink&gt; has claimed the combination of selexipag with its endothelin receptor antagonist &lt;ulink linkType="Drug" linkID="52854"&gt;macitentan&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="23780"&gt;Actelion&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="18552"&gt;Nippon Shinyaku&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="1232346"&gt;1232346&lt;/ulink&gt;] for treating pulmonary hypertension, as well diabetic arteriopathy, heart failure and erectile dysfunction. At the time of publication, the US (&lt;ulink linkType="Patent" linkID="PA6470597"&gt;US-20110136818&lt;/ulink&gt;) and European (&lt;ulink linkType="Patent" linkID="PA6432111"&gt;EP-02315587&lt;/ulink&gt;) equivalents were yet to be granted.&lt;/para&gt;&lt;para&gt;Apart from the aforementioned applications, there is another application, &lt;ulink linkType="Patent" linkID="PA6343929"&gt;WO-2011017612&lt;/ulink&gt;, filed by &lt;ulink linkType="Company" linkID="1021896"&gt;CoNCERT Pharmaceuticals&lt;/ulink&gt;, claiming deuterated derivatives of selexipag. The company has patenting history applying its deuterium chemistry technology on various drugs. There were no national or regional equivalents at the time of publication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Patients with PAH benefit from quite a large range of specific therapies, which can be administered alone or in combination, according to the functional class of PAH and disease progression. These therapeutic classes are represented by IP receptor agonists (eg, PGI2 and PGI2 derivatives), the endothelin receptor antagonists and the PDE5 inhibitors. However, there are several limiting factors associated with the use of these therapies.&lt;/para&gt;&lt;para&gt;PGI2, such as &lt;ulink linkType="Drug" linkID="6132"&gt;epoprostenol&lt;/ulink&gt;, induces a very short-lived vasodilation in patients with PAH and, in order to be effective, should be administered on a continuous basis. This consequently increases the risk of receptor desensitization and of the subsequent weaning of the therapeutic effect, as well as increases the risk of side effects, such as catheter-related sepsis, flush or hypotension [&lt;ulink linkType="Reference" linkID="1232015"&gt;1232015&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232017"&gt;1232017&lt;/ulink&gt;]. Its derivatives, such as &lt;ulink linkType="Drug" linkID="6149"&gt;iloprost&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="5943"&gt;beraprost&lt;/ulink&gt;, have a longer-lasting vasodilating effect and a less 'invasive' mode of administration, but still require high daily dose frequencies in order to be effective.&lt;/para&gt;&lt;para&gt;Endothelin receptor antagonists, such as &lt;ulink linkType="Drug" linkID="5871"&gt;bosentan&lt;/ulink&gt;, are administered orally once- or twice-daily, and have a well-demonstrated efficacy in patients with PAH. However, this therapy can be potentially hepatotoxic, especially when used on a long-term basis in patients with pre-existing liver disease [&lt;ulink linkType="Reference" linkID="1234020"&gt;1234020&lt;/ulink&gt;]. PDE5 inhibitors, such as &lt;ulink linkType="Drug" linkID="8713"&gt;sildenafil&lt;/ulink&gt;, are also administered orally and are effective as monotherapy or usually combined with endothelin receptor antagonists, especially in patients with less-advanced PAH. However, PDE5 inhibitors can also be associated, although not very frequently, with life-threatening side effects, such as sight impairment or coronary events [&lt;ulink linkType="Reference" linkID="1232060"&gt;1232060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Therefore, other therapies in the same drug classes that have better safety profiles or a longer half-life, as well as other molecules with a different mechanism of action, are still needed in PAH in order to enlarge the therapeutic armamentarium. In this regard in the first category, the IP receptor agonist selexipag might be able to fill the gap in the PGI2 therapeutic class. In contrast to other IP receptor agonists, selexipag is highly selective for the IP receptor, which should be advantageous, in particular with regards to side effects, such as those of the gastrointestinal tract. Promising efficacy data have been reported from a phase II, proof-of-concept clinical trial and pharmacokinetic analysis in phase I trials demonstrated a long half-life for the active form ACT-333679, which would bring significant advantages in reducing the number of daily doses.&lt;/para&gt;&lt;para&gt;In the second category, there are several other compounds that are currently being evaluated as potential PAH therapies. The novel endothelin receptor antagonist &lt;ulink linkType="Drug" linkID="52854"&gt;macitentan&lt;/ulink&gt; is a once-daily therapy currently in a phase III clinical trial (&lt;ulink linkType="Protocol" linkID="10630"&gt;NCT00660179&lt;/ulink&gt;) in patients with PAH, and it is hoped that this agent will be more efficacious and safer, especially on a long-term basis [&lt;ulink linkType="Reference" linkID="978321"&gt;978321&lt;/ulink&gt;]. Furthermore, an agent with a different mechanism, &lt;ulink linkType="Drug" linkID="54614"&gt;riociguat&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14455"&gt;Bayer&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="1207838"&gt;1207838&lt;/ulink&gt;], exerts its vasodilating effects by activating the soluble guanylate cyclase pathway of the NO-mediated pathway. &lt;ulink linkType="Drug" linkID="54614"&gt;Riociguat&lt;/ulink&gt; was well tolerated in phase I and II trials, and patients with PAH experienced significant decreases in pulmonary arterial pressure and increases in cardiac output and physical exercise tolerance [&lt;ulink linkType="Reference" linkID="1107766"&gt;1107766&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1036498"&gt;1036498&lt;/ulink&gt;]. At the time of publication, &lt;ulink linkType="Drug" linkID="54614"&gt;riociguat&lt;/ulink&gt; was being evaluated in phase III trials (&lt;ulink linkType="Protocol" linkID="49223"&gt;NCT00863681&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="38966"&gt;NCT00810693&lt;/ulink&gt;) in patients with PAH.&lt;/para&gt;&lt;para&gt;Additionally, tyrosine kinase inhibitors, which are drugs well known for their antiangiogenic activities, are also being evaluated for PAH [&lt;ulink linkType="Reference" linkID="1234087"&gt;1234087&lt;/ulink&gt;]. Their main antiproliferative and antiremodeling activities might qualify them for more advanced forms of PAH or for PAH refractory to the existing therapies. Existing clinical data with tyrosine kinase inhibitors, such as &lt;ulink linkType="Drug" linkID="11460"&gt;imatinib&lt;/ulink&gt;, support their use for PAH [&lt;ulink linkType="Reference" linkID="1154869"&gt;1154869&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1232062"&gt;1232062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;PAH is one of the rare, life-threatening diseases that has benefitted from extensive efforts to discover, develop and eventually commercialize effective therapies during the last decades. However, the quest for novel drugs has not stopped and currently drug discovery is focused in two main directions: (i) identification of novel molecules with new mechanisms of action and (ii) identification of 'more refined' compounds in the validated pharmacological classes. Selexipag falls in the latter category and it is hoped will address one of the many unmet medical needs still existent in PAH. The ongoing phase III clinical trial should provide valuable information about its likely success.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-21T00:00:00.000Z</StatusDate><Source id="1877316" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-01T00:00:00.000Z</StatusDate><Source id="2010519" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-20T00:00:00.000Z</StatusDate><Source id="2139882" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="PE">Peru</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-26T00:00:00.000Z</StatusDate><Source id="2076132" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19986">Handok Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-21T00:00:00.000Z</StatusDate><Source id="2009950" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-25T00:00:00.000Z</StatusDate><Source id="2075814" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-07T00:00:00.000Z</StatusDate><Source id="2104861" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-14T00:00:00.000Z</StatusDate><Source id="2076165" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-22T00:00:00.000Z</StatusDate><Source id="2075639" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-21T00:00:00.000Z</StatusDate><Source id="1775039" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-13T00:00:00.000Z</StatusDate><Source id="1661496" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3137">Spinal stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-01T00:00:00.000Z</StatusDate><Source id="2018730" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-02T00:00:00.000Z</StatusDate><Source id="2112392" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23780">Actelion Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-04-11T00:00:00.000Z</StatusDate><Source id="2136406" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="478">Raynauds disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="478">Raynauds disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-21T00:00:00.000Z</StatusDate><Source id="1679169" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23780">Actelion Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-21T00:00:00.000Z</StatusDate><Source id="2009950" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-21T00:00:00.000Z</StatusDate><Source id="898522" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-06T00:00:00.000Z</StatusDate><Source id="1601898" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-30T00:00:00.000Z</StatusDate><Source id="1601898" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-22T00:00:00.000Z</StatusDate><Source id="1638548" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-07T00:00:00.000Z</StatusDate><Source id="1198272" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-07T00:00:00.000Z</StatusDate><Source id="1198272" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-21T00:00:00.000Z</StatusDate><Source id="1773336" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-03T00:00:00.000Z</StatusDate><Source id="1638548" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-22T00:00:00.000Z</StatusDate><Source id="1723099" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-23T00:00:00.000Z</StatusDate><Source id="1622653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-02T00:00:00.000Z</StatusDate><Source id="1617245" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-22T00:00:00.000Z</StatusDate><Source id="1723099" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-31T00:00:00.000Z</StatusDate><Source id="1233938" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-03T00:00:00.000Z</StatusDate><Source id="1638548" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-07T00:00:00.000Z</StatusDate><Source id="1726726" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-07T00:00:00.000Z</StatusDate><Source id="1726726" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-21T00:00:00.000Z</StatusDate><Source id="1729521" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-28T00:00:00.000Z</StatusDate><Source id="1802950" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-28T00:00:00.000Z</StatusDate><Source id="1802950" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-21T00:00:00.000Z</StatusDate><Source id="1775039" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1265482" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-15T00:00:00.000Z</StatusDate><Source id="1773336" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-21T00:00:00.000Z</StatusDate><Source id="1877316" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-20T00:00:00.000Z</StatusDate><Source id="1865402" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-04T00:00:00.000Z</StatusDate><Source id="1723099" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1907982" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-30T00:00:00.000Z</StatusDate><Source id="1802950" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-16T00:00:00.000Z</StatusDate><Source id="1788525" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-22T00:00:00.000Z</StatusDate><Source id="1723099" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-26T00:00:00.000Z</StatusDate><Source id="1729521" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-16T00:00:00.000Z</StatusDate><Source id="1788525" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-30T00:00:00.000Z</StatusDate><Source id="2075828" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-12T00:00:00.000Z</StatusDate><Source id="1773336" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-11T00:00:00.000Z</StatusDate><Source id="1773336" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-18T00:00:00.000Z</StatusDate><Source id="1745410" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1788525" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-17T00:00:00.000Z</StatusDate><Source id="1745410" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-20T00:00:00.000Z</StatusDate><Source id="1865402" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-08T00:00:00.000Z</StatusDate><Source id="1795871" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-08T00:00:00.000Z</StatusDate><Source id="1795871" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-31T00:00:00.000Z</StatusDate><Source id="1233938" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate><Source id="2075828" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-02T00:00:00.000Z</StatusDate><Source id="541566" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-11-01T00:00:00.000Z</StatusDate><Source id="860460" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-21T00:00:00.000Z</StatusDate><Source id="898522" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-11-15T00:00:00.000Z</StatusDate><Source id="634927" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-21T00:00:00.000Z</StatusDate><Source id="898522" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="US">US</Country><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><AwardedIndication>Treatment of chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-02T00:00:00.000Z</MileStoneDate><Source id="2112392" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18552">Nippon Shinyaku Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><AwardedIndication>Chronic thromboembolic pulmonary hypertension which is persistent or recurrent after surgery or which is not ineligible for surgery</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-20T00:00:00.000Z</MileStoneDate><Source id="1775039" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="KR">South Korea</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary artery hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-11T00:00:00.000Z</MileStoneDate><Source id="1773336" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of primary pulmonary artery hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="AU">Australia</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>For the treatment of pulmonary arterial hypertension.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-25T00:00:00.000Z</MileStoneDate><Source id="1599346" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18552">Nippon Shinyaku Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-17T00:00:00.000Z</MileStoneDate><Source id="1598237" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18552">Nippon Shinyaku Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-17T00:00:00.000Z</MileStoneDate><Source id="1598237" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="US">US</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-30T00:00:00.000Z</MileStoneDate><Source id="1661496" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23780">Actelion Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-08-19T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18552">Nippon Shinyaku Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-08-26T00:00:00.000Z</MileStoneDate><Source id="1661496" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18552">Nippon Shinyaku Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-13T00:00:00.000Z</MileStoneDate><Source id="613808" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01171"><Name>IP prostanoid receptor</Name><SwissprotNumbers><Swissprot>P43119</Swissprot><Swissprot>P43252</Swissprot><Swissprot>P43253</Swissprot><Swissprot>P79393</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01609"><Name>Prostanoid receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2153678" linkType="reference" linkID="2153678"&gt;2153678&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2153445" linkType="reference" linkID="2153445"&gt;2153445&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18552">Nippon Shinyaku Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19986">Handok Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)c1cnc(c(n1)c2ccccc2)c3ccccc3</Smiles><Smiles>CC(C)N(CCCCOCC(=O)O)c1cnc(c(n1)c2ccccc2)c3ccccc3</Smiles></StructureSmiles><Deals><Deal id="111836" title="Actelion to develop Nippon Shinyaku's NS-304 outside Japan and codevelop in Japan "></Deal><Deal id="245846" title="Actelion to distribute Handok's Uptravi for pulmonary arterial hypertension in Korea"></Deal></Deals><PatentFamilies><PatentFamily id="1258562" number="WO-2009157398" title="Therapeutic agent for inflammatory bowel disease"></PatentFamily><PatentFamily id="2072499" number="WO-2009157396" title="Therapeutic agent for spinal canal stenosis"></PatentFamily><PatentFamily id="2075753" number="WO-2010018549" title="Therapeutic compositions containing macitentan"></PatentFamily><PatentFamily id="222960" number="WO-2009107736" title="Fibrosis inhibitor"></PatentFamily><PatentFamily id="2280171" number="WO-2010150865" title="Crystals"></PatentFamily><PatentFamily id="3000454" number="WO-2016161826" title="Method for preparing 4-isopropylamino-1-butanol"></PatentFamily><PatentFamily id="3424231" number="CN-106008364" title="A preparation method of selexipag"></PatentFamily><PatentFamily id="3444341" number="WO-2016180033" title="Method for preparing prostacyclin receptor agonist"></PatentFamily><PatentFamily id="3471235" number="WO-2016193994" title="Amorphous selexipag and process for preparation thereof"></PatentFamily><PatentFamily id="3548067" number="WO-2017029594" title="Processes for preparation of selexipag and its amorphous form"></PatentFamily><PatentFamily id="3563422" number="WO-2017040872" title="Solid state forms of selexipag"></PatentFamily><PatentFamily id="3572509" number="WO-2017042731" title="Amorphous form of selexipag and solid dispersion thereof"></PatentFamily><PatentFamily id="3572535" number="WO-2017042828" title="Process for the preparation of selexipag and intermediates thereof"></PatentFamily><PatentFamily id="3606882" number="WO-2017060827" title="An improved process for the preparation of selexipag or its pharmaceutically acceptable salts"></PatentFamily><PatentFamily id="3683109" number="WO-2017098998" title="Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide"></PatentFamily><PatentFamily id="3701270" number="WO-2017109772" title="Amorphous form of selexipag"></PatentFamily><PatentFamily id="3725866" number="WO-2017121806" title="Pharmaceutical composition of selexipag"></PatentFamily><PatentFamily id="3736496" number="CZ-201600317" title="The solid form of amorphous selexipag"></PatentFamily><PatentFamily id="3748545" number="CN-106957269" title="Preparation method for therapeutic drug selexipag for treating pulmonary arterial hypertension of adults"></PatentFamily><PatentFamily id="3808368" number="WO-2017168401" title="Process for the preparation of diphenylpyrazine derivatives"></PatentFamily><PatentFamily id="3870176" number="CN-107365275" title="Selexipag with high purity"></PatentFamily><PatentFamily id="3913899" number="WO-2018008042" title="Novel process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and novel polymorphs thereof"></PatentFamily><PatentFamily id="3926809" number="WO-2018015975" title="Amorphous solid dispersion of selexipag"></PatentFamily><PatentFamily id="3927250" number="WO-2018015974" title="Polymorphic forms and amorphous solid dispersion of selexipag"></PatentFamily><PatentFamily id="3939312" number="WO-2018022704" title="Crystalline form VI of selexipag"></PatentFamily><PatentFamily id="3998705" number="CN-107811970" title="A selexipag polycystic liposome and preparation method thereof"></PatentFamily><PatentFamily id="4039837" number="WO-2018078383" title="Pharmaceutical composition comprising amorphous selexipag"></PatentFamily><PatentFamily id="4095453" number="WO-2018109158" title="Selexipag formulation in liquisolid system"></PatentFamily><PatentFamily id="4190581" number="WO-2018162527" title="Pharmaceutical composition comprising selexipag"></PatentFamily><PatentFamily id="4354495" number="IN-201721010713" title="Preparing selexipag used to treat pulmonary arterial hypertension comprises e.g. reacting (4-((5,6-diphenyl-pyrazin-2-yl)-isopropyl-amino)-butoxy)-acetic acid with methane sulfonamide using coupling reagent and base, and crystallizing"></PatentFamily><PatentFamily id="4397606" number="WO-2019034094" title="Method for preparing alcoholic compound"></PatentFamily><PatentFamily id="4424553" number="CN-109384734" title="A preparation method of selexipag intermediate"></PatentFamily><PatentFamily id="4455335" number="WO-2019065792" title="Crystal"></PatentFamily><PatentFamily id="4506379" number="US-20190144397" title="Crystalline form of selexipag"></PatentFamily><PatentFamily id="4515688" number="WO-2019098300" title="Controlled release formulation"></PatentFamily><PatentFamily id="585236" number="WO-02088084" title="Heterocyclic compound derivatives and medicines"></PatentFamily><PatentFamily id="652086" number="WO-2011024874" title="Base addition salts"></PatentFamily><PatentFamily id="665501" number="WO-2009154246" title="Therapeutic agent for erectile dysfunction"></PatentFamily><PatentFamily id="740050" number="WO-2009157397" title="Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid anti-inflammatory agent"></PatentFamily><PatentFamily id="84986" number="WO-2011017612" title="Substituted diphenylpyrazine derivatives"></PatentFamily><PatentFamily id="871412" number="WO-2010010909" title="Therapeutic agent for chronic renal failure"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>10</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="HEC Pharm Co Ltd" id="1028084"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Megafine Pharma Pvt Ltd" id="1028929"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enaltec Labs Pvt Ltd" id="1053716"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mapi Pharma Ltd" id="1070245"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei University of Science and Technology" id="1071283"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai SynCores Technologies Inc" id="1076463"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Shiji Biological Technology Co Ltd" id="1120253"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing CoreTech Biomedical Co Ltd" id="1125003"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Seasons Biotechnology Co Ltd" id="1131256"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Maithri Drugs Private Ltd" id="1159049"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seasons Biotechnology (Taizhou) Co Ltd" id="1159999"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Alicorn Pharmaceutical Co Ltd" id="1173654"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd" id="1176077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Shinyaku Co Ltd" id="18552"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toray Industries Inc" id="20406"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apotex Inc" id="22353"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>